CANCER INCIDENCE & MORTALITY DATA SRI LANKA 2013



National Cancer Incidence and Mortality Data Sri Lanka 2013







National Cancer Control Programme

Ministry of Health
555/5 Public Health Complex
Elvitigala Mawatha,
Narahenpita, Colombo 05
Sri Lanka

15th Publication – National Cancer Incidence and Mortality Data Sri Lanka: 2013

Published date – March 2021

Acknowledgements

National Advisory Committee on Prevention & Control of Cancers

World Health Organization- Country Office, Sri Lanka

Cancer Care Association - Sri Lanka

Compiled by

Strategic Information and Management (SIM) Unit National Cancer Control Programme Sri Lanka

Published by





National Cancer Control Programme Ministry of Health 555/5 Public Health Complex Elvitigala Mawatha, Narahenpita, Colombo 05 Sri Lanka

Contact No +94 112368627, Fax +94 112368627 Email- nccpsl@yahoo.com Web – www.nccp.health.gov.lk



National Cancer Control Programme, Sri Lanka

Executive Summary

'Cancer Incidence Data Sri Lanka – 2013' is the 15th volume of the series of publication on cancer surveillance data of Sri Lanka. This is the output report of National Cancer Registry / Sri Lanka Cancer Registry (SLCR) based on newly reported cancers in the year 2013. The Cancer Incidence Data is collected through the government cancer treatment centres, pathology laboratories, Oral and Maxillo-Facial (OMF) surgery units in the country. As a new initiative of cancer surveillance from year 2012, the Population Based Cancer Registry (PBCR) of Colombo district was also commenced. The additional data sources considered for the Population Based Cancer Registry initiative in Colombo district were also incorporated to the national cancer registry database. All the data were entered into the CanReg 5 database. When processing the data, quality checks were conducted and duplicate entries were eliminated. Analysis was conducted using Can Reg 5 software and SPSS software.

In the year 2013, a total of 23,531 new patients with cancers were reported, giving a crude incidence rate (CR) of 114.3 per 100,000. Crude incidence rates of males and females were 114.0 /100,000 (n=11,364) and 114.6/100,000 (n=12,167). The highest 5-year age specific incidence rates were reported among males of 70-74 age group (740.4 /100,000) and females of 70-74 (442.0/100,000) age group. When age standardized rates (ASR) were considered, the overall ASR was 100.7 /100,000 and the ASR for males and females were 106.3/100,000 and 97.4/100,000 respectively. The absolute numbers, crude rates and age standardized rates were increased in relation to the similar figures of year 2012.

Lip, tongue & mouth (n=1755, ASR=16.1/100,000), Lung (n=1081, ASR = 10.2/100,000), Colon & rectum (n=835, CR=8.4/100,000) and Oesophagus (n=828, CR = 8.3/100,000) were the highest incident cancer among males. When the top ten cancers among males were considered the first four positions had remained same as the previous year.

Breast (n=3234, ASR =25.7/100,000), thyroid (n=1175, ASR = 9.8/100,000), cervix (n=895, ASR =7.0 /100,000), colorectal (n=865, CR=6.7/100,000) were the highest incident cancers among females. Thyroid cancer became the second commonest cancer among females while cervical cancer remained at third position. Compared with the 2012 data among females, colorectal cancer had come up in the list to 4th position pushing ovary cancer to 5th position.

Cumulative risk of developing cancer between the age group of 0-74 for males and females were 12.86% & 11.07% respectively. When sites of cancers were considered, highest cumulative risk of developing cancer between the age group of 0-74 males were reported for cancer of trachea, bronchus & lung (1.36%), mouth cancer (1.22%) and esophagus (0.97%). Similarly, highest cumulative risk of developing cancer between the age group of 0-74 females were reported for breast cancer (2.93%), thyroid cancer (0.88%) and cervical cancer (0.84%).

Among children and adolescents, the most common cancer was Leukemias, myeloproliferative diseases and myelodysplastic diseases(n=207), while lymphomas(n=88), CNS neoplasms(n=59), neuroblastomas and other peripheral nervous cell tumors (21) had positioned next in list respectively.

Mortality data received through Department of Census & Statistics and Annual Health Bulletin. A total of 7,166 (Crude death rate 71.9/100,000) and 5,788 (Crude death rate 54.5/100,000) cancer related deaths were reported among males and females respectively in the year 2013. Age specific death rates among females were lower than males and death rates were increasing over the advanced age. Malignant neoplasm of trachea, bronchus and lung is the leading cause of death among males and cancer of the breast is the leading cause of death among females.

Table of Contents

| | Page No |
|--|---------|
| Acknowledgements | 3 |
| Executive Summary | 4 |
| Table of Contents | 6 |
| List of Tables | 7 |
| List of Figures | 8 |
| Introduction | 9 |
| Methodology | 10 |
| Cancer Incidence Data of Sri Lanka –Tables and Figures | 16 |
| Mortality of Cancers | 40 |

List of Tables

| Section 1 – Cancer Incidence Data of Sri Lanka, 2013 O1 Population of Sri Lanka: sex distribution 2006 – 2013 O2 Cancer incidence by sex in Sri Lanka, 2006 – 2013 O3 Cancer incidence by 5-year age groups and sex in Sri Lanka, 2013 | 16 17 19 20 22 |
|---|----------------------------|
| 02 Cancer incidence by sex in Sri Lanka, 2006 – 2013 | 17 19 20 |
| | 19 20 |
| O2 Cancar incidence by 5 year ago groups and say in Sri Lanka 2012 | 20 |
| Cancel includince by 3-year age groups and sex in Str Lanka, 2013 | |
| 04 Leading cancer sites by sex in Sri Lanka, 2013 | 22 |
| O5 Cancer cases by 5-year age group among Males in Sri Lanka, 2013 | |
| O6 Cancer cases by 5-year age group among Females in Sri Lanka, 2013 | 26 |
| Number of incidence cancers by five-year age group and | |
| site among Males in Sri Lanka, 2013 | 30 |
| Number of incidence cancers by five-year age group and | |
| site among Females in Sri Lanka, 2013 | 31 |
| Age specific incidence rate, Crude incidence rate, Age standardized incidence rate per 100,000 population & Cumulative risk of cancers by five-year age group and site among Males in Sri Lanka, 2013 | 32 |
| Age specific incidence rate, Crude incidence rate, Age standardized incidence rate per 100,000 population & Cumulative risk of cancers by five-year age group and site among Females in Sri Lanka, 2013 | 33 |
| 11 Childhood & Adolescent (0-19) Cancer Incidence Data according to International Childhood Cancer Classification (ICCC-3) | 34 |
| Section 2 – Cancer Mortality Data of Sri Lanka 2013 | |
| Deaths due to cancers at the government hospitals in Sri Lanka, 2005-2013 | 40 |
| Deaths due to cancers out of all registered deaths in hospitals & field in Sri Lanka, 2005 – 2013 | 40 |
| Deaths due to cancers out of all registered deaths by sex in hospitals & field in Sri Lanka, 2005 – 2013 | 41 |
| 15 Leading sites (ICD-10) of cancer mortality – Male Sri Lanka 2013 | 42 |
| 16 Leading sites (ICD-10) of cancer mortality – Female Sri Lanka 2013 | 42 |

List of Figures

| Table | No Description | Page No |
|---------|--|---------|
| Section | 1 – Cancer Incidence Data of Sri Lanka 2013 | |
| 01 | General population in Sri Lanka by 5-year age groups in year 2013 (Population Pyramid) | 16 |
| 02 | Crude Cancer Incidence Rates in Sri Lanka, 2006 – 2013 | 18 |
| 03 | Age Standardized Cancer Incidence Rates in Sri Lanka, 2006 – 2013 | 18 |
| 04 | Cancer Incidence Rates in Sri Lanka – 2013 | 19 |
| 05 | Age Specific Cancer Incidence rates in Sri Lanka – 2013 | 20 |
| 06 | Proportion of leading cancers in Males in Sri Lanka – 2013 | 21 |
| 07 | Proportion of leading cancers in Females in Sri Lanka – 2013 | 21 |
| Section | 2 – Cancer Mortality Data of Sri Lanka 2013 | |
| 08 | Age Standardized mortality rates due to cancer in Sri Lanka, 2001 – 2013 | 41 |

Cancer Incidence & Mortality Data Sri Lanka – 2013

1. Introduction

Cancer surveillance (Cancer registration) is a process of systematic, continuous collection, storage, analysis, interpretation and dissemination of epidemiological information on cancers occurring in a country or a specific geographic area. Information generated from the cancer registration is essential for planning, implementation, monitoring and evaluation of cancer control activities of the country.

The National Cancer Control Programme (NCCP) of the Ministry of Health coordinates surveillance of cancers in Sri Lanka with the active participation of other stakeholders for cancer surveillance including cancer treatment centres, pathology laboratories, Oral and Maxillo Facial (OMF) units, professional colleges, WHO country office etc. The process of surveillance of cancers is technically guided by the International Agency for Research on Cancer (IARC) of WHO and WHO IARC Regional Hub for Cancer Registration, Mumbai India. In addition, technical guidance is received from Department of Epidemiology, Bis statistics and Cancer Registry, WIA Cancer Institute, Chennai India.

The information based on surveillance of cancers is published as a publication named 'Cancer Incidence Data Sri Lanka'. Up to now 14 volumes have been published as shown in Table 1. This publication is the 15th volume of Cancer Incidence Data Sri Lanka.

Table (i) Summary details of previous publications of 'Cancer Incidence Data Sri Lanka'

| Year of | | Publi | cation | | | | | |
|-----------------------------|--------------------------------|------------------------|--------------|----------------------------|---------------------|----------------------------|--------|-----------------------|
| cancer incidence data | Cancer Treatment Centres | Pathology laboratories | OMF units | Medical Record Rooms | Death Registrars | Total no. of centres | Volume | Year publishe d |
| 1985 | 3 | _ | | | _ | 3 | 1 | 1990 |
| 1986 | 3 | _ | I | I | _ | 3 | 2 | 1991 |
| 1987 | 3 | _ | I | I | _ | 3 | 3 | 1993 |
| 1990 | 3 | _ | | I | _ | 3 | 4 | 1996 |
| 1995 | 3 | _ | | | _ | 3 | 5 | 2002 |
| 2000 | 4 | _ | | | _ | 4 | 6 | 2006 |
| 2001-2005 | 5 | _ | | | _ | 5 | 7 | 2009 |
| 2006 | 6 | _ | 4 | | _ | 10 | 8 | 2012 |
| 2007 | 6 | _ | 4 | | _ | 10 | 9 | 2013 |
| 2008 | 7 | 16 | 17 | | _ | 40 | 10 | 2014 |
| 2009 | 9 | 15 | 17 | | _ | 41 | 11 | 2015 |
| 2010 | 9 | 13 | 17 | | _ | 39 | 12 | 2016 |
| 2011 | 9 | 13 | 12 | - | - | 34 | 13 | 2018 |
| 2012 | 9 | 37 | 15 | 9 | 40 | 110 | 14 | 2020 |

2. Methodology

Cancer Incidence Data

The methodology of surveillance for cancer incidence data includes (i) collection of cancer incidence data from the point of diagnosis /from the point of treatment, (ii) coding of cancer incidence data, (iii) entering of cancer incidence data to the database, (iv) duplicate checking & verification of data, (v) analysis of data and (vi) dissemination of information through the publication of 'Cancer Incidence Data Sri Lanka' and other modes.

The methodology of each step of cancer surveillance is described below.

2.1.1 Collection of cancer incidence data

Cancer incidence data were collected from cancer treatment centres, pathology laboratories and Oral & Maxillo-Facial (OMF) units throughout the country. In addition, the

2.1.1 Newly registered cancer patients at the cancer treatment centres

In the year 2013, there were 9 government cancer treatment centres involved in data collection (table i). Relevant data were extracted from cancer patients' clinic records using 'National Cancer Surveillance Form – H 1256'. Data were extracted by the medical officers, nursing officers and development officers attached to the cancer treatment centres, trained pre-intern medical graduates temporarily recruited through WHO Biennium funds and by the cancer registry staff of NCCP.

Table (ii) Distribution of government cancer treatment centres in year 2013

| Category of hospital | Name of the hospital | | | | | | | |
|------------------------------|--|--|--|--|--|--|--|--|
| National Hospitals | Apeksha Hospital - Maharagama (National Cancer | | | | | | | |
| | Institute) | | | | | | | |
| Teaching Hospitals | Kandy, Karapitiya, Anuradhapura, Batticaloa | | | | | | | |
| Provincial General Hospitals | Badulla, Kurunegala, Rathnapura | | | | | | | |
| Base Hospital | Telippalai (Jaffna) | | | | | | | |

2.1.2 Newly detected cancers at the pathology laboratories

The information on newly detected cancers at the pathology laboratories were received monthly through the 'Cancer Return Form - 1' (H-1290). A total of 38 Histopathology laboratories (12,299 diagnosed patients), 6 Haematology laboratories (378 diagnosed patients) and one oral pathology laboratory (429 diagnosed patients) have passively sent relevant data for the year 2013 (table ii).

 $Table\ (iii)\ Distribution\ of\ pathology\ laboratories\ which\ sent\ details\ of\ newly\ diagnosed$ $cancer\ patients\ in\ year\ 2013$

| Category of | Type of Pathology laboratory | | | | | | | | | |
|------------------|---------------------------------------|--------------|----------------|--|--|--|--|--|--|--|
| hospital | Histopathology | Haematology | Oral Pathology | | | | | | | |
| National | National Hospital of Sri Lanka | | | | | | | | | |
| Hospital | | | | | | | | | | |
| Teaching | De Soysa Hospital for Women, Castle | | | | | | | | | |
| Hospitals | Hospital for Women, Lady Ridgeway | | | | | | | | | |
| | Hospital, National Eye Hospital, | | | | | | | | | |
| | Colombo South, Colombo North, | | | | | | | | | |
| | National Hospital for Respiratory | | | | | | | | | |
| | Diseases-Welisara, . | | | | | | | | | |
| | Karapitiya,Kandy,Peradeniya, | | | | | | | | | |
| | Batticaloa | | | | | | | | | |
| Provincial | Kurunegala, Rathnapura, Badulla | Kurunegala | | | | | | | | |
| General | | ,Badulla | | | | | | | | |
| Hospitals | | | | | | | | | | |
| District General | Avissawella, Gampaha, Negombo, | Kalutara, | | | | | | | | |
| Hospitals | Kalutara, Nawalapitiya, Matale, | Hambanthota, | | | | | | | | |
| | Monaragala ,Chilaw, Vavuniya | Chilaw | | | | | | | | |
| | | ,Monaragala | | | | | | | | |
| Base Hospital | Homagama, Mulleriyawa, Wathupitiwala, | | | | | | | | | |
| | Kethumathi,Balapitiya, | | | | | | | | | |
| | Tangalle,Embilipitiya,Balangoda, | | | | | | | | | |
| | Gampola,Karawanella | | | | | | | | | |
| University | Faculty of Medicine - Colombo, | | Faculty of | | | | | | | |
| Units | Ruhuna | | Dental | | | | | | | |
| | | | Sciences - | | | | | | | |
| | | | Peradeniya | | | | | | | |
| Other | MRI | | | | | | | | | |
| Institutions | | | | | | | | | | |
| Private sector | - | | | | | | | | | |

2.1.3 Newly diagnosed cancers at the Oral & Maxillo - Facial (OMF) Surgery Units

Data on newly confirmed cancer patients at the Oral & Maxillo-Facial (OMF) surgery units were received annually through the Annual Notification Form of Oral Cancer (H -1294). A total of 15 OMF units have sent relevant data for year 2013 (table iii).

Table (iv) Distribution of OMF Units which sent details of newly diagnosed cancer patients in year 2013

| Category of hospital | Name of the hospital |
|------------------------------|---|
| National Hospital | Dental Institute Colombo |
| Teaching Hospitals | Colombo South, Colombo North, Karapitiya, Kandy |
| Provincial General Hospitals | Badulla, Kurunegala, Rathnapura |
| District General Hospitals | Gampaha, Kalutara, Chilaw, Kegalle, Polonnaruwa |
| Base Hospital | Kuliyapitiya, Panadura |
| University Units | |

2.1.4 Incorporation of additional cancer incidence data collected for the Population Based Cancer Registry – Colombo district

Two additional data sources were identified for capturing further cancer incidence data from Colombo district when commencing the Population Based Cancer Registry and those data sources were also incorporated as data generating centres for national cancer registry.

Details from Medical Record Departments of Hospitals situated in Colombo district & adjacent districts

The information on cancer patients treated at the secondary and tertiary care hospitals in the government sector, private sector and armed services in the Colombo district and selected hospitals in the adjacent districts were collected through the 'Cancer Return Form -2' (H-1291). A total of 25 Medical Record Departments have sent the details in year 2013 (table iv). Out

Table (v) Distribution of Medical Record Departments of Hospitals which sent details of newly diagnosed cancer patients in year 2013

| Category of hospital | Name of the hospital | | | | | | |
|----------------------------|--|--|--|--|--|--|--|
| National Hospital | National hospital, Dental Institute Colombo, Eye hospital, | | | | | | |
| | LRH, DMH, CSHW | | | | | | |
| Teaching Hospitals | Colombo South, Colombo North, Chest Hospital ,Sri | | | | | | |
| | Jayawardanapura | | | | | | |
| District General Hospitals | Avissawella, Gampaha ,Mulleriyawa | | | | | | |
| Base Hospital | Panadura, Horana | | | | | | |
| Private Sector hospitals | Asiri Central, Asiri Medical, Asiri Surgical, Durdans, Lanka | | | | | | |
| | Hospitals, Delmon, Oasis | | | | | | |
| Armed Services hospitals | Army hospital, Navy hospital, Police hospital | | | | | | |

Details from Divisional Death Registrars of the Colombo district

Details of all cancer related deaths registered by the Divisional Death Registrars of the Colombo district were received through the Cancer Return Form -3. A total of 40 divisional death registrars have sent relevant details for the year 2013.

2.2 Coding of cancer incidence data

According to the instructions of International Classification of Disease for Oncology 3rd edition (ICD-O 3), cancer incidence data were coded according to the site (Topography) and the histology (Morphology) of cancer. The cancer registry staff of the NCCP coded the cancer incidence data.

2.3 Entering of cancer incidence data to the database

Cancer incidence data were entered into the CanReg5 database by the trained data entry operators attached to the NCCP. The process of data entering was closely supervised by the cancer registry staff and was regularly involved in refresher training to the data entry operators to ensure accuracy and quality of data.

2.4 Duplicate checking & verification of data

While entering and confirming the data to the CanReg5 data base, duplicate checking was conducted using 'Person search' option of the CanReg 5 data base. In addition to the duplicate checking done through CanReg 5, further duplicate checking had to be conducted during the data verification stage as well to identify all possible duplicates.

The additional methods used were:

- i. Use of Linkpro software
- ii. Use of Excel software Sorted according to the descending or ascending order of selected variables

After removing possible duplicates, consistency checking and verification was conducted using 'IARCcrg' tool & MS Excel.

Mismatches according to;

Age/Incidence and birthdates

Age /Site /Histology

Site /Histology

Sex/Site

Sex/Histology

Behaviour /Site

Behaviour / Histology

Grade /Histology Basis of Diagnosis /Histology were corrected.

After these procedures, preliminary analysis was conducted using CanReg 5 & SPSS to detect further mismatches. Data sources up to the patient clinic files were rechecked in the instances where mismatches were noted by the cancer registry staff of the NCCP. After identifying errors or misclassifications, necessary corrections were done before finalizing the data for analysis.

2.5 Analysis of cancer incidence data

Analysis section of the CanReg 5 package, SPSS and MS Excel software were used to analyze cancer incidence data. The standard cancer registry tables described at the Cancer incidence in 5 continents (CI 5) were generated through CanReg 5 database.

The estimated population data for year 2013 for calculation cancer incidence & mortality data was received from the Department of Census & Statistics.

Table (vi) Estimated population for year 2013

| | Estimated Population |
|--------|----------------------|
| Male | 9,965,956 |
| Female | 10,619,085 |
| Total | 20,585,041 |

Source – Department of Census & Statistics of Sri Lanka

Cancer Mortality Data

Cancer mortality data were received through two sources at national level.

- (i) Hospital Indoor Morbidity Mortality Return of Medical Statistics unit of Ministry of Health
- (ii) Cause specific death data published by the Department of Census & Statistics.

Based on the available data further analysis was conducted.

Cancer Incidence Data of Sri Lanka

General population Sri Lanka 2013




Figure 1 : General population in Sri Lanka by 5-year age groups (Population Pyramid)

Table 1 : Population of Sri Lanka: sex distribution 2006 – 2013

| | | Year | | | | | | | |
|---------------|------|-------|-------|-------|-------|-------|-------|-------|--|
| | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | |
| Male ('000) | 9889 | 9956 | 10060 | 10148 | 10249 | 10381 | 9856 | 9965 | |
| Female ('000) | 9969 | 10083 | 10186 | 10302 | 10404 | 10511 | 10502 | 10619 | |
| Sex Ratio | 99.2 | 98.7 | 98.8 | 98.5 | 98.5 | 98.8 | 93.8 | 93.8 | |

Table 2 Cancer Incidence by sex, 2006-2013

| Year | Sex | Number | % | CR | ASR |
|------|--------|--------|----------|-------|-------|
| 2006 | Male | 6205 | 44.1 | 62.7 | 69.2 |
| | Female | 7875 | 55.9 | 79.0 | 79.5 |
| | Total | 14080 | | 70.9 | 74.2 |
| 2007 | Male | 6,356 | 46.6 | 63.8 | 70.9 |
| | Female | 7,279 | 53.4 | 72.2 | 72.8 |
| | Total | 13,635 | | 68.0 | 71.6 |
| 2008 | Male | 7695 | 46.6 | 76.5 | 85.5 |
| | Female | 8,816 | 53.4 | 86.6 | 88.0 |
| | Total | 16511 | | 81.6 | 86.4 |
| 2009 | Male | 7858 | 46.5 | 77.4 | 86.4 |
| | Female | 9030 | 53.5 | 87.7 | 89.1 |
| | Total | 16888 | | 82.6 | 87.5 |
| 2010 | Male | 7,993 | 4701 | 78.0 | 87.4 |
| | Female | 8,970 | 52.9 | 86.2 | 87.7 |
| | Total | 16,963 | | 82.1 | 87.3 |
| 2011 | Male | 8370 | 47.9 | 80.6 | 90.4 |
| | Female | 9,112 | 52.1 | 86.7 | 88.7 |
| | Total | 17482 | | 83.7 | 89.2 |
| 2012 | Male | 11363 | 49.1 | 115.3 | 107.8 |
| | Female | 11773 | 50.9 | 112.1 | 95.5 |
| | Total | 23136 | | 113.6 | 100.1 |
| 2013 | Male | 11364 | 48.3 | 114.0 | 106.3 |
| | Female | 12167 | 51.7 | 114.6 | 97.4 |
| | Total | 23531 | | 114.3 | 100.7 |




Figure 2 : Crude Cancer Incidence Rates-Sri Lanka, 2006 – 2013




Figure 3: Age Standardized Cancer Incidence Rates- Sri Lanka, 2006 - 2013




Figure 4 : Cancer Incidence Rates in Sri Lanka - 2013

Table 3 Cancer incidence by 5 year age groups & sex - 2013

| A ~~ | Male Femal | | Female | | | Total | | | |
|--------------|------------|-----------------|-----------|-------|-----------------|-----------|-------|-----------------|-----------|
| Age Group | Cases | Populati- on | Incidence | Cases | Populati- on | Incidence | Cases | Populati- on | Incidence |
| Unknown | 22 | | | 27 | | | 49 | | _ |
| 00-04 | 115 | 889230 | 12.9 | 102 | 874485 | 11.7 | 217 | 1763715 | 12.3 |
| 05-09 | 55 | 892056 | 6.2 | 56 | 875418 | 6.4 | 111 | 1767474 | 6.3 |
| 10-14 | 69 | 838363 | 8.2 | 61 | 820101 | 7.4 | 130 | 1658464 | 7.8 |
| 15-19 | 102 | 829051 | 12.3 | 109 | 833562 | 13.1 | 211 | 1662613 | 12.7 |
| 20-24 | 91 | 750463 | 12.1 | 167 | 799285 | 20.9 | 258 | 1549748 | 16.6 |
| 25-29 | 114 | 751731 | 15.2 | 229 | 818343 | 28.0 | 343 | 1570074 | 21.8 |
| 30-34 | 215 | 805683 | 26.7 | 440 | 851903 | 51.6 | 655 | 1657586 | 39.5 |
| 35-39 | 253 | 693603 | 36.5 | 603 | 731009 | 82.5 | 856 | 1424612 | 60.1 |
| 40-44 | 461 | 668902 | 68.9 | 848 | 705248 | 120.2 | 1309 | 1374150 | 95.3 |
| 45-49 | 780 | 624984 | 124.8 | 1167 | 675054 | 172.9 | 1947 | 1300038 | 149.8 |
| 50-54 | 1250 | 587732 | 212.7 | 1459 | 645191 | 226.1 | 2709 | 1232922 | 219.7 |
| 55-59 | 1509 | 506403 | 298.0 | 1606 | 569525 | 282.0 | 3115 | 1075928 | 289.5 |
| 60-64 | 1822 | 430082 | 423.6 | 1684 | 497822 | 338.3 | 3506 | 927904 | 377.8 |
| 65-69 | 1632 | 286828 | 569.0 | 1431 | 353263 | 405.1 | 3063 | 640091.2 | 478.5 |
| 70-74 | 1361 | 183810 | 740.4 | 1030 | 233023 | 442.0 | 2391 | 416832.9 | 573.6 |
| 75+ | 1514 | 227035 | 666.9 | 1148 | 335854 | 341.8 | 2662 | 562889 | 472.9 |
| Total | 11365 | 9965956 | 114.0 | 12167 | 10619085 | 114.6 | 23532 | 20585041 | 114.3 |

Table 4: Leading cancer sites by sex - 2013

| | Male | | | | | Fen | nale | | |
|--------------|----------------------------------|-------|-------|-------|------------------|-----------------------|-------|-------|------|
| ICD 10 | Site | No | CR | ASR | ICD 10 | Site | No | CR | ASR |
| C00-C06 | Lip, tongue and mouth | 1755 | 17.6 | 16.1 | C50 | Breast | 3234 | 30.5 | 25.7 |
| C33-C34 | Trachea, bronchus and lung | 1081 | 10.9 | 10.2 | C73 | Thyroid | 1175 | 11.1 | 9.8 |
| C18-C20 | Colon and rectum | 835 | 8.4 | 7.8 | C53 | Cervix Uteri | 895 | 8.4 | 7.0 |
| C15 | Oesophagus | 828 | 8.3 | 7.6 | C18-C20 | Colon and rectum | 865 | 8.1 | 6.7 |
| C61 | Prostate | 717 | 7.2 | 7.0 | C56 | Ovary | 783 | 7.4 | 6.3 |
| C09-C14 | Pharynx | 634 | 6.4 | 5.9 | C15 | Oesophagus | 676 | 6.4 | 5.2 |
| C32 | Larynx | 613 | 6.2 | 5.7 | C54- C55 | Uterus | 668 | 6.3 | 5.2 |
| C81-C86, C96 | Lymphoma | 537 | 5.4 | 5.1 | C00-C06 | Lip, tongue and mouth | 476 | 4.5 | 3.7 |
| C67 | Bladder | 434 | 4.4 | 4.1 | C81- C86, C96 | Lymphoma | 382 | 3.6 | 3.2 |
| C91-C95 | Leukaemia | 414 | 4.2 | 4.1 | C91-C95 | Leukaemia | 334 | 3.1 | 3.0 |
| All | sites | 11364 | 114.0 | 106.3 | | All Sites | 12167 | 114.6 | 97.4 |




Figure 5 - Age Specific Cancer Incidence rates -2013




Figure 6 - Proportion of leading cancers in Males in Sri Lanka – 2013




Figure 7 - Proportion of leading cancers in Females in Sri Lanka – 2013

Table 05: Cancer cases by 5 year age group among males in Sri Lanka – Male 2013

| | | | | | | | | | | | Age | e Group | | | | | | | |
|-------|--|----|-------|-------|-------|-------|-------|-------|-------|-------|-------|---------|-----------|-----------|-------|-------|-----------|-----------|-------|
| ICD 1 | 10 code and site | NK | 00-04 | 02-09 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 69-29 | 70-74 | 75+ | Total |
| C00 | Lip | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 4 | 5 | 11 | 12 | 7 | 4 | 10 | 56 |
| C01 | Base of tongue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 8 | 11 | 34 | 29 | 20 | 26 | 9 | 14 | 156 |
| C02 | Other and unspecified parts of tongue | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 6 | 9 | 28 | 63 | 68 | 89 | 67 | 44 | 34 | 38 | 449 |
| C03 | Gum | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 4 | 8 | 15 | 17 | 24 | 10 | 19 | 23 | 123 |
| C04 | Floor of mouth | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 9 | 15 | 28 | 17 | 19 | 23 | 12 | 14 | 141 |
| C05 | Palate | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 14 | 30 | 29 | 35 | 28 | 24 | 13 | 18 | 194 |
| C06 | Unspecified part of mouth | 1 | 0 | 0 | 0 | 0 | 1 | 2 | 6 | 12 | 24 | 63 | 74 | 105 | 83 | 96 | 77 | 92 | 636 |
| C07 | Parotid gland | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 4 | 6 | 3 | 3 | 8 | 5 | 9 | 4 | 7 | 5 | 57 |
| C08 | Unspecified major salivary gland | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 1 | 1 | 5 | 3 | 1 | 1 | 1 | 4 | 20 |
| C09 | Tonsil | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 12 | 22 | 22 | 30 | 24 | 28 | 17 | 11 | 168 |
| C10 | Other oropharynx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 7 | 9 | 18 | 20 | 24 | 12 | 14 | 3 | 109 |
| C11 | Nasopharynx | 0 | 0 | 0 | 0 | 5 | 1 | 0 | 3 | 1 | 0 | 2 | 6 | 1 | 9 | 3 | 6 | 1 | 38 |
| C12 | Piriform sinus | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 17 | 27 | 24 | 34 | 27 | 20 | 17 | 171 |
| C13 | Hypopharynx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 7 | 6 | 10 | 10 | 6 | 6 | 49 |
| C14 | Lip oral cavity and pharynx- unspcified | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 6 | 23 | 13 | 12 | 16 | 10 | 14 | 99 |
| C15 | Oesophagus | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 3 | 37 | 44 | 110 | 140 | 155 | 116 | 100 | 100 | 828 |
| C16 | Stomach | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 6 | 17 | 29 | 118 51 | 149 72 | 71 | 56 | 100 39 | 100 47 | 391 |
| C17 | small intestine | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 6 | 8 | 10 | 3 | 4 | 4 | 391 |
| C18 | Colon | 1 | 0 | 0 | 0 | 0 | 1 | 2 | 10 | 17 | 22 | 22 | 45 | 45 | 53 | 58 | 43 | 48 | 367 |
| C19 | Recto sigmoid | | | | | | | | | | | | | | | | | | |
| C20 | junction | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 3 | 5 | 4 | 4 | 12 | 8 | 11 | 12 | 61 |
| C20 | Rectum Anus and anal | 1 | 0 | 0 | 0 | 0 | 0 | 5 | 1 | 8 | 17 | 25 | 26 | 56 | 70 | 52 | 66 | 80 | 407 |
| C21 | canal | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 2 | 7 | 3 | 12 | 3 | 4 | 35 |
| C22 | Liver and intra hepatic bile duct | 1 | 5 | 0 | 1 | 1 | 0 | 0 | 0 | 2 | 4 | 4 | 15 | 19 | 42 | 37 | 41 | 37 | 209 |
| C23 | Gallbladder | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 6 | 3 | 2 | 1 | 18 |
| C24 | Unspecified part of billiary tract | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 6 | 10 | 8 | 7 | 5 | 6 | 6 | 53 |
| C25 | Pancreas Other and ill | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 6 | 9 | 12 | 8 | 12 | 9 | 5 | 11 | 74 |
| C26 | Other and ill- defined digestive organs | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 4 | 3 | 4 | 1 | 15 |
| C30 | Nasal cavity and middle ear | 1 | 3 | 0 | 0 | 2 | 0 | 0 | 2 | 2 | 2 | 1 | 2 | 5 | 9 | 1 | 5 | 2 | 37 |
| C31 | Accessory sinuses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 3 | 5 | 5 | 3 | 4 | 5 | 28 |
| C32 | Larynx | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 4 | 15 | 54 | 76 | 96 | 118 | 110 | 65 | 70 | 613 |
| C33 | Trachea | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 0 | 2 | 2 | 0 | 0 | 8 |

| | | | | | | | | | | | Age | Group | | | | | | | |
|--------|---|----|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-----|-------|
| ICD 10 | 0 code and site | NK | 90-00 | 60-50 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 69-99 | 70-74 | 75+ | Total |
| C34 | Bronchus and lung | 2 | 0 | 0 | 0 | 0 | 0 | 3 | 6 | 8 | 19 | 52 | 108 | 153 | 229 | 212 | 150 | 132 | 1074 |
| C37 | Other thoracic organs | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 2 | 2 | 2 | 1 | 0 | 5 | 4 | 1 | 0 | 22 |
| C38 | Heart, mediastinum and pleura | 0 | 0 | 1 | 0 | 0 | 2 | 7 | 3 | 2 | 3 | 2 | 0 | 3 | 4 | 0 | 4 | 0 | 31 |
| C39 | Other and ill- defined sites of intrathoracic organs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| C40 | Bone and articular cartilage of limbs | 0 | 2 | 2 | 5 | 10 | 5 | 4 | 5 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 37 |
| C41 | Bone and articular cartilage of limbs | 0 | 0 | 1 | 2 | 2 | 4 | 2 | 4 | 3 | 0 | 1 | 3 | 1 | 0 | 0 | 0 | 3 | 26 |
| C43 | Melanoma of skin | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 1 | 1 | 3 | 0 | 6 | 3 | 5 | 8 | 8 | 10 | 48 |
| C44 | Other skin | 1 | 0 | 0 | 1 | 0 | 3 | 2 | 2 | 6 | 17 | 18 | 27 | 42 | 40 | 34 | 24 | 37 | 254 |
| C45 | Mesothelioma Peripheral | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 6 |
| C47 | nerves and autonomic nervous system Retroperitoneu | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 2 | 1 | 1 | 2 | 0 | 1 | 0 | 2 | 12 |
| C48 | m and peritoneum | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 2 | 2 | 2 | 1 | 0 | 1 | 11 |
| C49 | Other connective and soft tissue | 0 | 6 | 1 | 6 | 3 | 1 | 5 | 6 | 3 | 9 | 10 | 5 | 13 | 14 | 7 | 10 | 10 | 119 |
| C50 | Breast | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 3 | 2 | 6 | 7 | 11 | 15 | 7 | 0 | 9 | 64 |
| C60 | Penis | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 4 | 6 | 9 | 14 | 11 | 12 | 14 | 24 | 98 |
| C61 | Prostate | Ī | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 4 | 20 | 27 | 102 | 148 | 184 | 227 | 717 |
| C62 | Testis | 0 | 1 | 2 | 1 | 1 | 4 | 8 | 13 | 5 | 4 | 7 | 2 | 1 | 2 | 1 | 0 | 2 | 54 |
| C63 | Other and unspecified male genital organs | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 4 |
| C64 | Kidney | 0 | 1 0 | 2 | 1 | 2 | 0 | 0 | 7 | 8 | 6 | 20 | 30 | 26 | 40 | 29 | 20 | 28 | 229 |
| C65 | Renal pelvis | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| C66 | Ureter | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 1 | 0 | 0 | 5 |
| C67 | Bladder | 1 | 0 | 0 | 1 | 2 | 0 | 2 | 4 | 1 | 12 | 12 | 27 | 41 | 88 | 85 | 75 | 83 | 434 |
| C68 | Other and unspecified part of urinary organs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 6 | 0 | 2 | 10 |
| C69 | Eye | 0 | 8 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 2 | 3 | 3 | 0 | 1 | 20 |
| C70 | Meninges | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 5 |
| C71 | Brain | 0 | 6 | 5 | 6 | 5 | 3 | 3 | 14 | 19 | 13 | 15 | 19 | 17 | 21 | 13 | 6 | 6 | 171 |
| C72 | Other parts of central nervous system | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 3 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 10 |
| C73 | Thyroid gland | 0 | 1 | 0 | 4 | 1 | 9 | 1 | 27 | 35 | 29 | 17 | 25 | 31 | 25 | 17 | 13 | 13 | 265 |

| C74 A C75 G G C76 G C81 H C81 H C82 H C82 H C83 H | Adrenal gland Other endocrine glands Other and ill defined site Unknown primary Hodgkin disease Follicular(nodul ar) non-Hodgkin lymphoma Diffuse non-Hodgkin lymphoma Peripheral and | 0 0 0 1 3 0 | 8 0 4 1 | 1 0 1 1 | 0 0 1 0 0 | 0 0 0 2 | 0 0 0 | 8 0 0 | 1 0 90-34 | 1 0 | 1 40-44 | 1 45.49 | 1 6-68 | 0 | 2 | 1 0 | 1 0 70-74 | 1 0 | 19 3 |
|---|---|----------------------------|------------------|---------|-----------|---------|-------|-------|-----------|-----|---------|---------|--------|----|-----|-----|-----------|-----|---------|
| C75 | Other endocrine glands Other and ill defined site Unknown primary Hodgkin disease Follicular(nodul ar) non- Hodgkin lymphoma Diffuse non- Hodgkin lymphoma Peripheral and | 0 1 3 0 | 0 4 1 | 0 1 1 | 0 0 | 0 | 0 | 0 0 0 | 0 | 0 | 0 | | | | 2 | | | | |
| C75 | Other endocrine glands Other and ill defined site Unknown primary Hodgkin disease Follicular(nodul ar) non- Hodgkin lymphoma Diffuse non- Hodgkin lymphoma Peripheral and | 0 1 3 0 | 0 4 1 | 0 1 1 | 0 0 | 0 | 0 | 0 | 0 | 0 | 0 | | | | 2 | | | | |
| C76 C76 C81 F C82 F 1 | glands Other and ill defined site Unknown primary Hodgkin disease Follicular(nodul ar) non- Hodgkin lymphoma Diffuse non- Hodgkin lymphoma Peripheral and | 1 3 0 | 4 | 1 | 0 | 0 | 0 | 0 | | | | 1 | 0 | 0 | | 0 | 0 | 0 | 3 |
| C76 C81 F C81 F C82 F F F C82 F F F C83 F F F C83 F F F C83 F F F F C83 F F F F F F F F F F F F F F F F F F F | defined site Unknown primary Hodgkin disease Follicular(nodul ar) non- Hodgkin lymphoma Diffuse non- Hodgkin lymphoma Peripheral and | 3 | 1 | 1 | 0 | | | | 1 | 2 | | | | U | 1 | U | | | |
| C81 C82 F I I C83 F I | Follicular(nodul ar) non- Hodgkin lymphoma Diffuse non- Hodgkin lymphoma Peripheral and | 0 | | | | 2 | 1 | 3 | | | 1 | 2 | 3 | 6 | 7 | 9 | 4 | 9 | 50 |
| C82 II I C83 II | ar) non- Hodgkin lymphoma Diffuse non- Hodgkin lymphoma Peripheral and | | 1 | 1 | 3 | | | ر | 9 | 11 | 31 | 67 | 100 | 96 | 111 | 112 | 88 | 96 | 732 |
| C83 I | Hodgkin lymphoma Peripheral and | 0 | | | | 8 | 1 2 | 5 | 4 | 9 | 6 | 8 | 6 | 7 | 5 | 3 | 3 | 0 | 81 |
| | | | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 3 | 3 | 7 | 1 | 0 | 4 | 28 |
| C84 c | cutaneous T- cell lymphoma | 0 | 5 | 6 | 4 | 9 | 1 | 6 | 2 | 3 | 2 | 7 | 5 | 12 | 10 | 6 | 8 | 14 | 100 |
| C85 t | Other and unspecified types of non- Hodgkin lymphoma | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 3 | 3 | 2 | 5 | 4 | 1 | 21 |
| C86 t | Other and unspecified types of non- Hodgkin lymphoma | 0 | 3 | 2 | 3 | 8 | 1 | 5 | 10 | 9 | 13 | 17 | 39 | 37 | 39 | 33 | 29 | 39 | 296 |
| coo i | Immunoprolifer itive diseases Multiple | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 0 | 0 | 3 |
| C90 r | myeloma and malignant plasma cell neoplasm | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| | lymphoid leukaemia | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 4 | 15 | 20 | 23 | 38 | 25 | 33 | 29 | 192 |
| | Myeloid leukaemia | 0 | 3 | 2 | 2 | 17 | 9 | 1 | 10 | 4 | 3 | 6 | 9 | 9 | 6 | 5 | 10 | 8 | 186 |
| | Monocytic leukaemia | 0 | 2 | 2 | 5 | 13 | 3 | 7 | 17 | 10 | 15 | 13 | 17 | 21 | 22 | 21 | 13 | 12 | 193 |
| C94 l | Other leukaemia of specified cell | 0 | 2 | 2 | | 2 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 1 | 2 | 3 | 0 | 18 |
| C95 u | type Leukaemia of unspecified cell type | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 0 | 7 |
| C96 l | Other neoplasms of lymphoid, haematopoeitic and related | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 2 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 2 | 1 | 10 |
| C97 1 s | other leukaemia of specified cell typeB | 0 | 5 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 8 |
| D45 I | Polycythemia vera | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 2 | 0 | 2 | 1 | 0 | 7 |
| | Myelodysplasti c syndromes | 0 | 0 | 1 | | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 2 | 3 | 4 | 3 | 2 | 9 | 27 |
| (r u t D47 t | Other neoplasms of uncertain or unknown behaviour of lymphoid, haematopoietic | 0 | 0 | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 4 |

| | | | | | | | | | | Age | Group | | | | | | | |
|----------------------|----|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|------|-------|
| ICD 10 code and site | NK | 90-04 | 60-50 | 10-14 | 15-19 | 20-24 | 67-57 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 65-55 | 60-64 | 69-59 | 70-74 | 75+ | Total |
| Total | 22 | 115 | 55 | 69 | 102 | 91 | 114 | 215 | 253 | 461 | 780 | 1250 | 1509 | 1822 | 1632 | 1361 | 1514 | 11365 |

 $Table \ 06: \ Cancer \ cases \ by \ 5 \ year \ age \ group \ among \ females \ in \ Sri \ Lanka-Female \ 2013$

| | | | | | | | | | | A | ge Grou | ір | | | | | | | | |
|-----|--|----|-------|-------|-------|-------|-------|-------|-------|--------|---------|-------|-------|-------|-------|-------|-------|--------|---|---------|
| 10 | CD 10 code and site | NK | 00-04 | 02-00 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 69-29 | 70-74 | 75+ | | Total |
| C00 | Lip | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 4 | 3 | 1 | 4 | 0 | 17 |
| C01 | Base of tongue | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 6 | 3 | 7 | 2 | 0 | 21 |
| C02 | Other and unspecified parts of tongue | | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 6 | 12 | 13 | 20 | 20 | 13 | 17 | 1 | 0 | 11 |
| C03 | Gum | | 0 | 0 | 0 | 0 | 0 | Ō | 0 | Ō | 1 | 1 | 1 | 3 | 7 | 5 | 5 | 3 | 0 | 36 |
| C04 | Floor of mouth | | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 4 | 3 | 3 | 3 | 0 | 13 |
| C05 | Palate | | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 3 | 1 | 2 | 2 | 2 | 7 | 5 | 1 | 0 | 34 |
| C06 | Other and unspecified parts of mouth | | 0 | 0 | 0 | 0 | 0 | 1 | 4 | 5 | 1 | 6 | 22 | 24 | 46 | 32 | 35 | 5 | 0 | 23 |
| C07 | Parotid gland | | 0 | 0 | 2 | 1 | 3 | 2 | 3 | 2 | 6 | 3 | 2 | 4 | 3 | 4 | 3 | 3 | 0 | 9 41 |
| C08 | Other and unspecified major salivary gland | | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 1 | 2 | 1 | 3 | 2 | 1 | 1 | 0 | 14 |
| C09 | Tonsil | | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 2 | 1 | 4 | 4 | 1 | 2 | 0 | 16 |
| C10 | Oropharynx | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 1 | 3 | 0 | 2 | 2 | 0 | 14 |
| C11 | Nasopharynx | | 0 | 0 | 0 | 3 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 0 | 15 |
| C12 | Pyriform sinus | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 5 | 3 | 2 | 4 | 0 | 18 |
| C13 | Hypopharynx | | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 3 | 2 | 7 | 7 | 2 | 3 | 4 | 0 | 29 |
| C14 | Other and ill-defined sites | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 5 | 3 | 1 | 4 | 5 | 0 | 20 |
| C15 | Oesophagus | | 0 | 0 | 0 | 0 | 0 | 1 | 4 | 1 | 7 | 24 | 59 | 95 | 12 | 12 | 99 | 1 | 0 | 67 |
| C16 | Stomach | | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 8 | 11 | 16 | 23 | 3 | 1 | 22 | 2 | 0 | 6 |
| C17 | Small intestine | | | | | | | | | | | 11 | 16 | | 28 | 21 | 23 | 9 | 0 | 15 3 |
| C18 | Colon | | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 3 | 3 | 2 | 3 | 5 | 7 | 2 | 3 | 0 | 31 |
| | | | 0 | 0 | 0 | 0 | 1 | 0 | 1 2 | 1 7 | 3 | 39 | 58 | 57 | 58 | 65 | 50 | 4 7 | 2 | 44 0 |
| C19 | Rectosigmoid junction | | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 3 | 4 | 9 | 6 | 8 | 8 | 10 | 6 | 0 | 57 |
| C20 | Rectum | | 0 | 0 | 0 | 0 | 0 | 3 | 9 | 9 | 1 | 27 | 35 | 54 | 63 | 59 | 36 | 5 | 1 | 36 |
| | | | | | | | | | | | 8 | | | | | | | 4 | | 8 |

| | | | | | | | | | | A | ge Grou | ір | | | | | | | | |
|-----|---|----|-------|-------|-------|-------|-------|-------|-------|-------|---------|-------|-------|-------|-------|-------|-------|-----|---|---------|
| 10 | CD 10 code and site | NK | 00-04 | 02-09 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 69-59 | 70-74 | 75+ | | Total |
| C21 | Anus and anal canal | | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 2 | 3 | 5 | 7 | 2 | 7 | 4 | 4 | 0 | 37 |
| C22 | Liver and intrahepatic bile duct | | 8 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 4 | 2 | 9 | 9 | 7 | 11 | 12 | 1 | 1 | 84 |
| C23 | Gallbladder | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 9 | 3 | 4 | 3 | 6 | 5 | 0 | 34 |
| C24 | Other and unspecified parts of biliary tract | | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 2 | 9 | 7 | 7 | 9 | 6 | 4 | 4 | 0 | 50 |
| C25 | Pancreas | | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 2 | 7 | 9 | 10 | 12 | 12 | 14 | 3 | 5 | 0 | 77 |
| C26 | Other and ill-defined digestive organs | | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 2 | 3 | 2 | 4 | 0 | 2 | 0 | 15 |
| C30 | Nasal cavity and middle ear | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 1 | 2 | 3 | 8 | 2 | 1 | 2 | 0 | 22 |
| C31 | Accessory sinuses | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 1 | 3 | 1 | 1 | 4 | 0 | 13 |
| C32 | Larynx | | 0 | 1 | 0 | 0 | 1 | 0 | 3 | 1 | 3 | 6 | 5 | 7 | 7 | 6 | 7 | 9 | 0 | 56 |
| C33 | Trachea | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 3 |
| C34 | Bronchus and lung | | 0 | 0 | 0 | 1 | 0 | 1 | 7 | 1 | 1 | 29 | 35 | 42 | 52 | 59 | 40 | 3 | 1 | 32 |
| C37 | Thymus | | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 5 | 2 | 1 | 3 | 1 | 4 | 2 | 0 | 1 | 0 | 7 17 |
| C38 | Heart, mediastinum and pleura | | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 1 | 1 | 0 | 0 | 1 | 2 | 0 | 0 | 9 |
| C40 | Bone and articular cartilage of limbs | | 0 | 3 | 5 | 5 | 2 | 4 | 1 | 2 | 1 | 0 | 3 | 0 | 3 | 1 | 0 | 1 | 0 | 31 |
| C41 | Bone and articular cartilage of other and unspecified sites | | 2 | 2 | 2 | 3 | 3 | 4 | 0 | 5 | 0 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 31 |
| C43 | Melanoma of skin | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 2 | 5 | 4 | 3 | 3 | 8 | 2 | 0 | 32 |
| C44 | Other malignant neoplasms of skin | | 0 | 0 | 0 | 1 | 1 | 3 | 3 | 5 | 3 | 9 | 19 | 23 | 29 | 18 | 33 | 4 | 1 | 19 |
| C45 | Mesothelioma | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 3 | 2 | 1 | 1 | 0 | 10 |
| C47 | Peripheral nerves and autonomic nervous system | | 1 | 1 | 0 | 2 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 7 |
| C48 | Retroperitoneum and peritoneum | | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 2 | 1 | 1 | 2 | 3 | 1 | 0 | 0 | 0 | 12 |
| C49 | Connective, subcutaneous and other soft tissue | | 3 | 4 | 3 | 6 | 2 | 2 | 6 | 6 | 1 | 8 | 8 | 7 | 9 | 14 | 6 | 8 | 0 | 10 2 |
| C50 | Breast | | 0 | 0 | 0 | 1 | 4 | 2 | 1 | 1 | 3 | 45 | 48 | 47 | 44 | 32 | 21 | 1 | 9 | 32 |

| | | | | | | | | | | A | ge Grou | ıp | | | | | | | | |
|-----|---|----|-------|-------|-------|-------|--------|-------|-------|-------|---------|---------|---------|---------|-------|-------|-------|-----|---|----------|
| I | CD 10 code and site | NK | 00-04 | 05-09 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 69-29 | 70-74 | 75+ | | Total |
| | | | | | | | | 8 | 0 | 8 | 2 | 9 | 0 | 8 | 0 | 2 | 1 | 8 | | 34 |
| C51 | Vulva | | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 9 | 4 | 3 | 3 | 0 | 1 | 1 | 1 | 9 | 0 | 22 |
| C52 | Vagina | | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 1 | 2 | 3 | 2 | 5 | 9 | 6 | 5 | 2 | 0 | 45 |
| C53 | Cervix uteri | | 0 | 0 | 0 | 0 | 1 | 3 | 9 | 3 | 5 | 97 | 14 | 14 | 12 | 12 | 77 | 8 | 2 | 89 |
| C54 | Corpus uteri | | 0 | 0 | 1 | 0 | 2 | 4 | 5 | 4 | 9 | 32 | 2 83 | 4 95 | 4 | 1 80 | 47 | 2 | 0 | 5 51 |
| C55 | Uterus not specified | | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 2 | 6 | 15 | 14 | 27 | 9 28 | 16 | 19 | 2 | 3 | 3 15 |
| C56 | Ovary | | | | | | | | | | | | | | | | | 9 | | 5 |
| | , | | 3 | 1 | 7 | 1 4 | 1 | 1 | 3 | 2 | 5 7 | 94 | 11 | 12 | 92 | 10 | 42 | 5 | 1 | 78 3 |
| C57 | Other and unspecified female genital organs | | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 2 | 3 | 2 | 8 | 0 | 2 | 2 | 2 | 0 | 23 |
| C58 | Placenta | | 0 | 0 | 0 | 0 | 2 | 4 | 3 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 13 |
| C64 | Kidney | | 8 | 6 | 1 | 0 | 1 | 1 | 2 | 1 | 3 | 10 | 11 | 10 | 16 | 14 | 6 | 5 | 0 | 95 |
| C65 | Renal pelvis | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| C66 | Ureter | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 0 | 0 | 0 | 4 |
| C67 | Bladder | | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 2 | 3 | 6 | 8 | 10 | 17 | 12 | 18 | 2 | 0 | 98 |
| C68 | Other and unspecified urinary organs | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 |
| C69 | Eye and adnexa | | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 0 | 1 | 0 | 23 |
| C70 | Meninges | | 7 | 0 | 0 | 0 | 0 | 0 | 1 | 4 | 1 | 4 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 14 |
| C71 | Brain | | 4 | 1 | 9 | 7 | 2 | 1 | 1 | 9 | 1 | 19 | 14 | 11 | 15 | 7 | 6 | 4 | 0 | 15 |
| C72 | Spinal cord, cranial nerves and other parts of central nervous system | | 1 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 7 |
| C73 | Thyroid gland | | 0 | 1 | 6 | 4 | 7 9 | 9 | 1 5 | 1 | 1 3 | 11 7 | 91 | 86 | 80 | 43 | 26 | 3 | 1 | 11 75 |
| C74 | Adrenal gland | | 3 | 1 | 0 | 0 | 0 | 0 | 5 | 4 | 9 | 0 | 2 | 2 | 1 | 0 | 0 | 0 | 0 | 15 |
| C75 | Other endocrine glands and related structures | | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| C76 | Other and ill-defined sites | | 6 | 0 | 0 | 0 | 0 | 1 | 0 | 4 | 1 | 1 | 3 | 5 | 3 | 3 | 2 | 1 | 2 | 42 |
| | | | | | | | | | | | | | | | | | | 1 | | |

| | | | | | | | | | | A | ge Grou | ıp | | | | | | | | |
|-----|--|----|-------|-------|-------|-------|-------|-------|-------|-------|---------|-------|-------|-------|-------|-------|-------|------|-----|---------|
| 10 | CD 10 code and site | NK | 00-04 | 05-09 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 69-59 | 70-74 | 75+ | | Total |
| C80 | Unknown primary | | 1 | 0 | 1 | 0 | 5 | 6 | 6 | 1 | 2 | 33 | 44 | 62 | 70 | 72 | 44 | 5 | 1 | 43 |
| C81 | Hodgkin disease | | 0 | 1 | 4 | 0 | 1 | 1 | 5 | 5 | 2 3 | 2 | 4 | 2 | 2 | 3 | 2 | 0 | 0 | 2 59 |
| C82 | Follicular (nodular) non- Hodgkin lymphoma | | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 4 | 1 | 1 | 3 | 3 | 9 | 3 | 3 | 3 | 0 | 31 |
| C83 | Diffuse non-Hodgkin lymphoma | | 1 | 0 | 2 | 2 | 1 | 4 | 1 | 4 | 2 | 4 | 4 | 6 | 7 | 9 | 5 | 7 | 0 | 59 |
| C84 | Peripheral and cutaneous T-cell lymphoma | | 1 | 0 | 1 | 1 | 0 | 1 | 4 | 1 | 2 | 1 | 1 | 0 | 3 | 1 | 2 | 1 | 0 | 20 |
| C85 | Other and unspecified types of non-Hodgkin lymphoma | | 0 | 1 | 0 | 1 | 3 | 7 | 1 | 9 | 7 | 7 | 25 | 32 | 24 | 26 | 25 | 2 | 0 | 20 |
| C86 | Other lymphoma | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| C88 | Immunoproliferative diseases | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 3 |
| C90 | Multiple myeloma and malignant plasma cell neoplasms | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 6 | 20 | 15 | 27 | 28 | 21 | 2 | 0 | 14 9 |
| C91 | Lymphoid leukaemia | | 2 | 1 | 7 | 6 | 6 | 5 | 6 | 2 | 0 | 2 | 4 | 2 | 5 | 9 | 3 | 5 | 0 | 99 |
| C92 | Myeloid leukaemia | | 5 | 2 | 7 | 4 | 5 | 4 | 1 | 9 | 1 | 13 | 18 | 27 | 23 | 17 | 14 | 1 | 1 | 19 |
| go. | | | | | | | | | 2 | | 2 | | | | | | | 9 | | 2 |
| C93 | Monocytic leukaemia Other leukaemia of | | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 3 | 3 | 0 | 1 | 0 | 10 |
| C95 | specified cell type Leukaemia of unspecified cell type | | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 3 | 0 | 2 | 2 | 1 | 1 | 1 | 0 | 0 | 0 | 13 |
| C96 | Other and unspecified malignant neoplasms of lymphoid, hematopoietic | | 8 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 20 |
| D45 | and related tissue Polycythaemia vera | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 3 |
| D46 | Myelodysplastic syndromes | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 1 | 2 | 3 | 6 | 3 | 0 | 19 |
| D47 | Other neoplasms of uncertain behaviour of lymphoid, haematopoietic and related tissue | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 2 | 2 | 0 | 5 |
| | Total | | 102 | 99 | 61 | 109 | 167 | 229 | 440 | 603 | 848 | 1167 | 1459 | 1606 | 1684 | 1431 | 1030 | 1148 | 7.7 | 12167 |

Table 7 Number of incidence cancers by five-year age group and site among Males in Sri Lanka, 2013

Cancer Registry (2013) General population Sri lanka 2013

Cases by age group (Period) - Male

| SITE | ALL A | | 0- | 5- | 10- | 15- | 20- | 25- | 30- | 35- | 40- | 45- | 50- | 55- | 60- | 65- | 70- | 75+ | (%) | ICD (10th) |
|---|--|--------------------------------------|-------------------|------------------|--------------|---------------|------------------|--------------|----------------------------------|-----------------------------------|--|--|--|--|--|--|--|--|---|---|
| Lip Tongue Mouth Salivary glands Tonsil Other oropharynx Nasopharynx Hypopharynx Pharynx unspecified | 56 605 1094 77 168 109 38 220 99 | 0 0 1 0 0 0 0 | 1 | | | 1 | 1 2 | 3 4 | 1 6 11 6 - 1 3 | 2 14 14 7 2 1 1 | 36 51 4 12 7 - 7 2 | 4 74 116 4 22 9 2 19 6 | 5 102 146 13 22 18 6 34 23 | 11 118 174 8 30 20 1 30 13 | 12 87 154 10 24 24 9 44 12 | 7 70 153 5 28 12 3 37 16 | 4 43 121 8 17 14 6 26 10 | 10 52 147 9 11 3 1 23 14 | 0.5 5.4 9.8 0.7 1.5 1.0 0.3 2.0 | C00 C01-02 C03-06 C07-08 C09 C10 C11 C12-13 C14 |
| Oesophagus Stomach Small intestine Colon Rectum Anus Liver Gallbladder etc. Pancreas | 828 391 39 367 468 35 209 71 74 | 1 0 1 1 0 1 1 0 | 5 | | 1 | 1 | 1 1 | 2 5 1 | 5 - 10 2 1 | 3 6 1 17 9 - 2 | 37 17 1 22 20 1 4 6 | 44 29 1 22 30 1 4 7 | 118 51 6 45 30 2 15 11 | 149 72 8 45 60 7 19 10 8 | 155 71 10 53 82 3 42 13 | 116 56 3 58 60 12 37 8 | 100 39 4 43 77 3 41 8 5 | 100 47 4 48 92 4 37 7 | 7.5 3.5 0.4 3.3 4.2 0.3 1.9 0.6 0.7 | C15 C16 C17 C18 C19-20 C21 C22 C23-24 C25 |
| Nose, sinuses etc. Larynx Trachea, bronchus and lung Other thoracic organs | 65 613 1081 53 | 1 1 2 0 | 3 - | : | - | - | - - - 3 | - 3 9 | 2 4 6 5 | 4 4 8 4 | 3 15 19 5 | 1 54 53 4 | 76 110 1 | 10 96 153 3 | 14 118 231 9 | 110 214 4 | 65 150 5 | 70 132 | 0.6 5.5 9.7 0.5 | C30-31 C32 C33-34 C37-38 |
| Bone Melanoma of skin | 63 48 | 0 | 2 | 3 | 7 | 12 | 9 | 6 | 9 | 4 | - 3 | 2 | 3 | 1 3 | 1 | 1 8 | - 8 | 3 10 | 0.6 0.4 | C40-41 C43 |
| Other skin | 254 | 1 | - | - | 1 | - ' | 3 | 2 | 2 | 6 | 17 | 18 | 27 | 42 | 40 | 34 | 24 | 37 | 2.3 | C44 |
| Mesothelioma Kaposi sarcoma Connective and soft tissue | 6 0 131 | 0 0 0 | 6 | 1 | - 6 | - 4 | 12 | 5 | 1 - 7 | 3 | 11 | 11 | - 6 | 15 | 1 - 14 | - 8 | 1 - 10 | 1 12 | 0.1 0.0 1.2 | C45 C46 C47,C49 |
| Breast | 64 | 1 | - | - | - | - | - | 1 | 2 | 3 | 2 | 6 | 7 | 11 | 15 | 7 | - | 9 | 0.6 | C50 |
| Penis Prostate Testis Other male genital organs | 98 717 54 4 | 0 1 0 0 | 1 1 1 | 2 | 1 | 1 | 4 | - 8 1 | 13 | 3 - 5 | 4 3 4 | 4 7 | 20 2 | 14 27 1 | 11 102 2 | 12 148 1 1 | 14 184 | 24 227 2 1 | 0.9 6.5 0.5 0.0 | C60 C61 C62 C63 |
| Kidney Renal pelvis Ureter Bladder Other urinary organs | 229 1 5 434 10 | 0 0 0 1 | 10 - - - | 2 | 1 - 1 | 2 - 2 - | - | 2 | 7 - - 4 | 8 - - 1 | 6 - 12 | 20 - 12 1 | 30 1 27 | 26 1 2 41 | 40 - 1 88 1 | 29 - 1 85 6 | 20 - - 75 - | 28 - 83 2 | 2.1 0.0 0.0 3.9 0.1 | C64 C65 C66 C67 C68 |
| Eye Brain, nervous system Thyroid Adrenal gland Other endocrine | 20 186 265 19 3 | 0 0 0 0 | 8 7 1 8 | 1 5 - 1 | 7 4 - | 6 1 | 3 9 - | 18 - | 1 16 27 1 | 23 35 1 | 15 29 1 | 16 17 1 | 20 25 1 | 19 31 | 21 25 2 1 | 3 13 17 1 | 6 13 1 | 1 6 13 1 | 0.2 1.7 2.4 0.2 0.0 | C69 C70-72 C73 C74 C75 |
| Hodgkin disease Non-Hodgkin lymphoma Immunoproliferative diseases Multiple myeloma | 81 453 3 192 | 0 0 0 | 1 13 - | 9 - | 3 7 - | 8 19 1 | 12 12 - | 13 - 1 | 14 - 2 | 9 16 2 2 | 6 16 - 4 | 27 15 | 50 - 20 | 7 55 23 | 5 58 - 38 | 45 25 | 3 41 - 33 | 58 29 | 0.7 4.1 0.0 1.7 | C81 C82-85,C96 C88 C90 |
| Lymphoid leukaemia Myeloid leukaemia Leukaemia unspecified Myeloproliferative disorders Myelodysplastic syndromes | 186 218 10 11 27 | 0 0 0 0 | 36 5 1 | 21 5 - | 23 6 - | 17 15 1 | 9 3 - - | 10 7 - | 10 17 2 | 4 10 - 1 1 | 16 - 1 | 14 1 | 18 1 - | 9 24 - 2 3 | 24 - 1 4 | 5 24 1 3 | 10 18 2 2 2 | 12 1 1 2 | 1.7 2.0 0.1 0.1 0.2 | C91 C92-94 C95 MPD MDS |
| Other and unspecified | 812 | 6 | 5 | 2 | - | 2 | 1 | 3 | 11 | 14 | 32 | 71 | 108 | 104 | 124 | 126 | 96 | 107 | 7.3 | O&U |
| All sites | 11364 | 22 | 115 | 55 | 69 | 102 | 91 | 114 | 215 | 253 | 461 | 779 | 1250 | 1509 | 1822 | 1632 | 1361 | 1514 | | ALL |
| All sites but C44 | 11110 | 21 | 115 | 55 | 68 | 102 | 88 | 112 | 213 | 247 | 444 | 761 | 1223 | 1467 | 1782 | 1598 | 1337 | 1477 | 100.0 | ALLbC44 |

Table builtThu Dec 31 14:53:10 IST 2020 by CanReg5.

Table 8 Number of incidence cancers by five-year age group and site among Females in Sri Lanka,2013

Cancer Registry (2013) General population Sri lanka 2013

Cases by age group (Period) - Female

| SITE | ALL A | | | 0- | 5- | 10- | 15- | 20- | 25- | 30- | 35- | 40- | 45- | 50- | 55- | 60- | 65- | 70- | 75+ | (%) | ICD (10th) |
|---|--|---------------------------------|---|-------------------|-------------------|-------------|---------------|-----------------------------|---------------------------------|-----------------------------------|---|---|---|---|---|--|--|---|--|---|---|
| Lip Tongue Mouth Salivary glands Tonsil Other oropharynx Nasopharynx Hypopharynx Pharynx unspecified | 17 137 322 55 16 14 15 47 20 | 0 0 0 0 0 0 | | | | 2 | 1 1 | 1 3 - 1 | 2 2 - | 5 6 1 | 1 5 2 - 1 | 1 6 15 6 - 1 1 | 1 12 9 4 1 3 1 4 | 1 13 25 4 2 3 1 3 | 2 23 29 5 1 1 1 8 5 | 4 26 59 6 4 3 1 12 3 | 3 16 47 6 4 - 2 5 | 1 24 48 4 1 2 1 5 | 15 77 4 2 2 2 8 5 | 0.1 1.1 2.7 0.5 0.1 0.1 0.1 0.4 0.2 | C00 C01-02 C03-06 C07-08 C09 C10 C11 C12-13 C14 |
| Oesophagus Stomach Small intestine Colon Rectum Anus Liver Gallbladder etc. Pancreas | 676 153 31 440 425 37 84 84 77 | 0 0 0 2 1 0 1 | | 8 | 1 | 1 | 1 | 1 1 | 1 1 1 - 3 1 - | 4 1 1 12 10 - 1 | 11 - 17 11 2 - 2 2 | 7 8 3 34 21 2 4 3 7 | 24 11 3 39 31 3 2 11 | 59 16 2 58 44 5 9 16 | 95 23 3 57 60 7 9 10 | 123 28 5 58 71 2 7 13 12 | 121 21 7 65 67 7 11 9 | 99 23 2 50 46 4 12 10 3 | 132 19 3 47 60 4 19 9 | 5.6 1.3 0.3 3.7 3.5 0.3 0.7 0.7 0.7 | C15 C16 C17 C18 C19-20 C21 C22 C23-24 C25 |
| Nose, sinuses etc. Larynx Trachea, bronchus and lung Other thoracic organs Bone | 35 56 330 26 62 | 0 0 1 0 | | - | 1 1 | : | - 1 - | 1 - 1 | - - 1 1 | 3 7 1 | 3 1 15 1 | 1 3 14 4 | 1 6 29 2 | 4 5 37 4 | 4 7 42 1 | 11 7 53 4 | 3 6 59 3 | 2 7 40 2 | 6 9 31 1 | 0.3 0.5 2.8 0.2 | C30-31 C32 C33-34 C37-38 C40-41 |
| Melanoma of skin Other skin | 32 192 | 0 | | - | - | - | -, | -, | - 3 | - 3 | 2 | 3 | 2 | 5 | 4 23 | 3 29 | 3 18 | 8 | 2 | 0.3 1.6 | C43 C44 |
| Mesothelioma Kaposi sarcoma Connective and soft tissue | 10 0 109 | 0 0 0 | | 4 | 5 | 3 | - 8 | 2 | 2 | 7 | 1 - 6 | 10 | - 9 | - 8 | 2 - 8 | 3 - 9 | 2 14 | 1 - 6 | 1 - 8 | 0.1 0.0 0.9 | C45 C46 C47,C49 |
| Breast | 3234 | 9 | | - | - | | 1 | 4 | 28 | 100 | 189 | 324 | 459 | 480 | 478 | 440 | 322 | 211 | 189 | 27.0 | C50 |
| Vulva Vagina Cervix uteri Corpus uteri Uterus unspecified Ovary Other female genital organs Placenta | 22 45 895 513 155 783 23 13 | 0 2 0 3 1 0 | | 3 | 1 | 1 7 | 14 | 1 1 2 16 2 2 | 3 4 13 | 2 9 5 3 33 | 1 34 7 2 26 | 2 59 16 9 57 2 | 3 97 32 15 94 3 | 142 83 14 110 2 | 5 144 95 27 120 8 | 124 109 28 92 | 121 80 16 101 2 | 5 77 47 19 42 2 | 12 9 82 32 19 53 2 | 0.2 0.4 7.5 4.3 1.3 6.5 0.2 0.1 | C51 C52 C53 C54 C55 C56 C57 C58 |
| Kidney Renal pelvis Ureter Bladder Other urinary organs | 95 1 4 98 2 | 0 0 0 0 | | 8 | 6 - - - | 1 | - | 1 | 1 - 2 | - | 1 - 2 1 | 3 - - 3 | 10 - - 6 | 11 - 8 | 10 - 1 10 | 16 1 17 | 14 - 2 12 1 | 6 - 18 | 5 - 20 | 0.8 0.0 0.0 0.8 0.0 | C64 C65 C66 C67 C68 |
| Eye Brain, nervous system Thyroid Adrenal gland Other endocrine | 23 171 1175 15 2 | 0 0 1 0 0 | | 17 5 - 3 | 1 11 1 1 | 9 | 10 44 - | 79 - | 10 94 | 13 155 5 | 13 174 | 13 139 1 | 24 117 | 14 91 2 1 | 12 86 2 | 1 16 80 1 | 3 7 43 | 7 26 | 1 5 39 - | 0.2 1.4 9.8 0.1 0.0 | C69 C70-72 C73 C74 C75 |
| Hodgkin disease Non-Hodgkin lymphoma Immunoproliferative diseases Multiple myeloma | 149 | 0 0 0 | | 10 - | 1 4 | 3 | 4 | 16 4 - | 13 13 - | 5 15 - | 18 1 | 12 - 3 | 13 - 6 | 33 20 | 2 41 1 15 | 2 43 - 27 | 3 39 - 28 | 35 21 | 35 1 29 | 0.5 2.7 0.0 1.2 | C81 C82-85,C96 C88 C90 |
| Lymphoid leukaemia Myeloid leukaemia Leukaemia unspecified Myeloproliferative disorders Myelodysplastic syndromes | 99 215 20 8 19 | 0 1 0 0 | | 25 7 2 - | 12 3 1 | 7 8 - | 6 4 1 | 5 2 | 5 4 - | 13 | 12 2 | 12 2 1 | 16 1 1 | 20 1 1 | 2 28 2 | 5 27 3 1 | 9 21 1 - | 14 1 2 6 | 5 20 1 2 3 | 0.8 1.8 0.2 0.1 0.2 | C91 C92-94 C95 MPD MDS |
| Other and unspecified | 502 | 3 | | 8 | | 1 | 1 | 5 | 8 | 6 | 19 | 26 | 35 | 50 | 73 | 78 | 80 | 46 | 63 | 4.2 | O&U |
| All sites | 12167 | 27 | 1 | 02 | 56 | 61 | 109 | 167 | 229 | 440 | 603 | 848 | 1167 | 1459 | 1606 | 1684 | 1431 | 1030 | 1148 | | ALL |
| All sites but C44 | 11975 | 26 | 1 | 02 | 56 | 61 | 108 | 166 | 226 | 437 | 598 | 845 | 1158 | 1440 | 1583 | 1655 | 1413 | 997 | 1104 | 100.0 | ALLbC44 |

Table builtThu Dec 31 14:53:10 IST 2020 by CanReg5.

Table 9 Age specific incidence rate, Crude incidence rate, Age standardized incidence rate per 100,000 population & Cumulative risk of cancers by five-year age group and site among Males in Sri Lanka, 2013

Cancer Registry (2013)

General population Sri lanka 2013

Incidence per 100,000 by age group (Period) - Male

| SITE | ALL A | | (|)- | 5- | 10- | 15- | 20- | 25- | 30- | 35- | 40- | 45- | 50- | 55- | 60- | 65- | 70- | 75+ | CRUDE (%) CUM CUM ASR ICD (10th) | |
|---|--|--------------------------------------|----------------------|----------|------------------------|-------------------|-------------------|-------------------|--------------------------|--|---|---|---|---|--|---|--|---|--|---|--------|
| Lip Tongue Mouth Salivary glands Tonsil Other oropharynx Nasopharynx Hypopharynx Pharynx unspecified | 56 605 1094 77 168 109 38 220 99 | 0 0 1 0 0 0 0 | 0. | 1 | | | 0.1 | 0.1 0.3 0.1 | 0.4 | 0.1 0.7 1.4 0.7 0.1 0.4 | 0.3 2.0 2.0 1.0 0.3 0.1 0.1 | 5.4 7.6 0.6 1.8 1.0 1.0 0.3 | 0.6 11.8 18.6 0.6 3.5 1.4 0.3 3.0 1.0 | 0.9 17.4 24.8 2.2 3.7 3.1 1.0 5.8 3.9 | 2.2 23.3 34.4 1.6 5.9 3.9 0.2 5.9 2.6 | 2.8 20.2 35.8 2.3 5.6 5.6 2.1 10.2 2.8 | 2.4 24.4 53.3 1.7 9.8 4.2 1.0 12.9 5.6 | 2.2 23.4 65.8 4.4 9.2 7.6 3.3 14.1 5.4 | 4.4 22.9 64.7 4.0 4.8 1.3 0.4 10.1 6.2 | 0.6 0.5 0.03 0.06 0.5 C00 6.1 5.4 0.41 0.65 5.5 C01-6 11.0 9.8 0.63 1.22 10.1 C03-6 0.8 0.7 0.05 0.08 0.7 C07-6 1.7 1.5 0.10 0.20 1.6 C09 1.1 1.0 0.08 0.14 1.0 C10 0.4 0.3 0.02 0.05 0.4 C11 2.2 2.0 0.13 0.27 2.1 C12-1 1.0 0.9 0.05 0.11 0.9 C14 | 6 8 |
| Oesophagus Stomach Small intestine Colon Rectum Anus Liver Gallbladder etc. Pancreas | 828 391 39 367 468 35 209 71 74 | 1 1 0 1 1 0 1 1 | 0. | 6 | | 0.1 | 0.1 | 0.1 | 0.3 0.3 0.7 0.1 | 0.6 1.2 0.2 0.1 | 0.4 0.9 0.1 2.5 1.3 0.3 | 5.5 2.5 0.1 3.3 3.0 0.1 0.6 0.9 0.9 | 7.0 4.6 0.2 3.5 4.8 0.2 0.6 1.1 1.4 | 20.1 8.7 1.0 7.7 5.1 0.3 2.6 1.9 2.0 | 29.4 14.2 1.6 8.9 11.8 1.4 3.8 2.0 1.6 | 36.0 16.5 2.3 12.3 19.1 0.7 9.8 3.0 2.8 | 40.4 19.5 1.0 20.2 20.9 4.2 12.9 2.8 3.1 | 54.4 21.2 22 23.4 41.9 1.6 22.3 4.4 2.7 | 44.0 20.7 1.8 21.1 40.5 1.8 16.3 3.1 4.8 | 8.3 7.5 0.50 0.97 7.6 C15 3.9 3.5 0.24 0.44 3.6 C16 0.4 0.4 0.3 0.04 0.4 C17 3.7 3.3 0.20 0.42 3.4 C18 4.7 4.2 0.23 0.55 4.4 C19-2 0.4 0.3 0.01 0.04 0.3 C21 2.1 1.9 0.09 0.27 2.0 C22- 0.7 0.6 0.05 0.08 0.7 C23-2 0.7 0.7 0.05 0.07 0.7 C25- | |
| Nose, sinuses etc. Larynx Trachea, bronchus and lung Other thoracic organs | 65 613 1081 53 | 1 1 2 0 | 0. | 0 | .1 | - | 0.2 | 0.4 | 0.4 1.2 | 0.2 0.5 0.7 0.6 | 0.6 0.6 1.2 0.6 | 0.4 2.2 2.8 0.7 | 0.2 8.6 8.5 0.6 | 0.9 12.9 18.7 0.2 | 2.0 19.0 30.2 0.6 | 3.3 27.4 53.7 2.1 | 1.4 38.4 74.6 1.4 | 4.9 35.4 81.6 2.7 | 3.1 30.8 58.1 | 0.7 0.6 0.04 0.07 0.6 C30-3 6.2 5.5 0.36 0.73 5.7 C32 10.8 9.7 0.58 1.36 10.2 C33-3 0.5 0.5 0.04 0.06 0.5 C37-3 | 4 8 |
| Melanoma of skin | 63 48 254 | 0 0 | 0. | 2 0 | 1.3 | 0.8 | 0.1 | 0.3 0.4 | 0.8 | 0.1 0.2 | 0.6 0.1 0.9 | 0.4 2.5 | 0.3 | 0.5 1.0 | 0.2 0.6 8.3 | 1.2 | 0.3 2.8 11.9 | 4.4 13.1 | 1.3 4.4 16.3 | 0.6 0.6 0.04 0.04 0.6 C40-4 0.5 0.4 0.02 0.06 0.5 C43 2.5 2.3 0.15 0.27 2.3 C44 | l |
| Other skin Mesothelioma Kaposi sarcoma Connective and soft tissue | 6 0 131 | 0 0 0 | | 7 0 | | 0.7 | 0.1 | 1.6 | 0.3 | 0.1 | 0.9 | 1.6 | 2.9 | 4.6 - 1.0 | 0.2 | 9.3 0.2 3.3 | 2.8 | 0.5 | 0.4 | 0.1 0.1 0.00 0.01 0.1 C46 0.0 0.0 0.00 0.00 0.0 C46 1.3 1.2 0.08 0.12 1.3 C47,C | 49 |
| Breast | 64 | 1 | | | | - | - | _ | 0.1 | 0.2 | 0.4 | 0.3 | 1.0 | 1.2 | 2.2 | 3.5 | 2.4 | - | 4.0 | 0.6 0.6 0.05 0.06 0.6 C50 | |
| Penis Prostate Testis Other male genital organs | 98 717 54 4 | 0 1 0 | 0. 0. 0. | 1 0 | 1.2 | 0.1 | 0.1 | 0.5 | 1.1 0.1 | 1.6 | 0.4 | 0.6 0.4 0.6 | 1.0 0.6 1.1 | 1.5 3.4 0.3 | 2.8 5.3 0.2 | 2.6 23.7 0.5 | 4.2 51.6 0.3 0.3 | 7.6 100.1 | 10.6 100.0 0.9 0.4 | 1.0 0.9 0.04 0.10 0.9 C60 7.2 6.5 0.17 0.93 7.0 C61 0.5 0.5 0.04 0.04 0.5 C62 0.0 0.0 0.00 0.00 0.0 C63 | |
| Kidney Renal pelvis Ureter Bladder Other urinary organs | 229 1 5 434 10 | 0 0 0 1 | 1. | 1 0 | 1.2 - - | 0.1 0.1 | 0.2 | : | 0.3 | 0.9 - 0.5 | 1.2 - 0.1 | 0.9 - 1.8 | 3.2 1.9 0.2 | 5.1 0.2 4.6 | 5.1 0.2 0.4 8.1 | 9.3 0.2 20.5 0.2 | 0.3 29.6 2.1 | 10.9 - 40.8 | 12.3 36.6 0.9 | 2.3 2.1 0.14 0.24 2.2 C64 0.0 0.0 0.00 0.00 0.0 C65 0.1 0.0 0.00 0.01 0.0 C65 4.4 3.9 0.19 0.54 4.1 C67 0.1 0.1 0.00 0.01 0.1 C68 | |
| Eye Brain, nervous system Thyroid Adrenal gland Other endocrine | 20 186 265 19 3 | 0 0 0 0 | 0. 0. 0. 0. | 8 0 1 | 1.1 1.6 1.1 | 0.8 0.5 0.1 | 0.7 0.1 | 0.4 | 0.4 | 0.1 2.0 3.4 0.1 | 3.3 5.0 0.1 | 2.2 4.3 0.1 | 2.6 2.7 0.2 0.2 | 0.2 3.4 4.3 0.2 | 0.4 3.8 6.1 | 0.7 4.9 5.8 0.5 0.2 | 1.0 4.5 5.9 0.3 | 3.3 7.1 0.5 | 0.4 2.6 5.7 0.4 | 0.2 0.2 0.01 0.02 0.2 0.69 1.9 1.7 0.13 0.17 1.7 0.70-7 2.7 2.4 0.18 0.24 2.4 0.73 0.2 0.2 0.01 0.02 0.2 0.2 0.74 0.0 0.0 0.0 0.00 0.0 0.75 | 2 |
| Hodgkin disease Non-Hodgkin lymphoma Immunoproliferative diseases Multiple myeloma | 81 453 3 192 | 0 0 0 | 0. 1. | 5 1 | 0.1 .0 - | 0.4 | 1.0 2.3 0.1 | 1.6 1.6 | 0.7 1.7 0.1 | 0.5 1.7 0.2 | 1.3 2.3 0.3 0.3 | 0.9 2.4 0.6 | 1.3 4.3 2.4 | 1.0 8.5 3.4 | 1.4 10.9 4.5 | 1.2 13.5 8.8 | 1.0 15.7 8.7 | 1.6 22.3 18.0 | 25.5 12.8 | 0.8 0.7 0.06 0.07 0.8 C81- 4.5 4.1 0.26 0.45 4.3 C81-8 0.0 0.0 0.00 0.00 0.0 C88 1.9 1.7 0.10 0.24 1.8 C90 | 5,C96 |
| Lymphoid leukaemia Myeloid leukaemia Leukaemia unspecified Myeloproliferative disorders Myelodysplastic syndromes | 186 218 10 11 27 | 0 0 0 0 | 4. 0. 0. | 6 0 | 1.4 1.6 - 1.1 | 2.7 | 2.1 1.8 0.1 | 0.4 0.1 | 1.3 0.9 - | 1.2 2.1 0.2 | 0.6 1.4 0.1 0.1 | 0.4 2.4 0.1 0.1 | 1.0 2.2 0.2 | 1.5 3.1 0.2 0.3 | 1.8 4.7 - 0.4 0.6 | 1.4 5.6 0.2 0.9 | 1.7 8.4 0.3 1.0 1.0 | 5.4 9.8 1.1 1.1 1.1 | 3.5 5.3 0.4 0.4 4.0 | 1.9 1.7 0.11 0.14 2.0 C92 2.2 2.0 0.13 0.22 2.1 C92-6 0.1 0.1 0.00 0.01 0.1 C93 0.1 0.1 0.00 0.02 0.1 MPD 0.3 0.2 0.01 0.02 0.2 MDS | 4 |
| Other and unspecified | 812 | 6 | 0. | | 1.2 | - | 0.2 | 0.1 | 0.4 | 1.4 | 2.0 | 4.8 | 11.4 | 18.4 | 20.5 | 28.8 | 43.9 | 52.2 | 47.1 | 8.1 7.3 0.45 0.93 7.6 O&U | |
| All sites | 11364 | 22 | 12. | | .2 | 8.2 | 12.3 | 12.1 | 15.2 | 26.7 | 36.5 | 68.9 | 124.6 | 212.7 | 298.0 | 423.6 | 569.0 | 740.4 | 666.9 | 114.0 6.30 12.86 106.5 ALL | |
| All sites but C44 | 11110 | 21 | 12. | 9 6 | .2 | 8.1 | 12.3 | 11.7 | 14.9 | 26.4 | 35.6 | 66.4 | 121.8 | 208.1 | 289.7 | 414.3 | 557.1 | 727.4 | 650.6 | 111.5 100.0 6.15 12.59 104.2 ALLb |)44 |

, Reference population: World Standard Population

Table builtFri Dec 11 13:52:43 IST 2020 by CanReg5.

Table 10 Age specific incidence rate, Crude incidence rate, Age standardized incidence rate per 100,000 population & Cumulative risk of cancers by five-year age group and site among Females in Sri Lanka,2013

Cancer Registry (2013)

General population Sri lanka 2013

Incidence per 100,000 by age group (Period) - Female

| Immunoproliferative diseases 3 0 0 0 0 0 0 0 0 0 | SITE | ALL A | | 0- | 5- | 10- | 15- | 20- | 25- | 30- | 35- | 40- | 45- | 50- | 55- | 60- | 65- | 70- | 75+ | CRUDE (%) CUM CUM ASR ICD (10th) |
|--|---|--|----------------------------|--------------------|-------------------|-----|------|---------------------------------|--------------------------|---------------------------------|---------------------------------|---|---|---|--|---|---|--|---|---|
| Stomatics 153 0 | Tongue Mouth Salivary glands Tonsil Other oropharynx Nasopharynx Hypopharynx Pharynx unspecified | 137 322 55 16 14 15 47 20 | 0 0 0 0 0 0 | - | | 0.2 | 0.1 | 0.4 | 0.2 | 0.7 0.1 - 0.1 | 0.7 0.3 - 0.1 | 0.9 2.1 0.9 - 0.1 0.1 0.1 | 1.8 1.3 0.6 0.1 0.4 0.1 | 2.0 3.9 0.6 0.3 0.5 0.2 0.5 | 4.0 5.1 0.9 0.2 0.2 0.2 1.4 0.9 | 5.2 11.9 1.2 0.8 0.6 0.2 2.4 0.6 | 4.5 13.3 1.7 1.1 0.6 1.4 0.3 | 10.3 20.6 1.7 0.4 0.9 0.4 2.1 1.7 | 4.5 22.9 1.2 0.6 0.6 0.6 2.4 1.5 | 1.3 1.1 0.07 0.14 1.1 C01-02 3.0 2.7 0.13 0.30 2.5 C03-06 0.5 0.5 0.03 0.05 0.5 C07-08 0.2 0.1 0.01 0.02 0.1 C09 0.1 0.1 0.01 0.01 0.1 C10 0.1 0.1 0.01 0.01 0.1 C11 0.4 0.4 0.03 0.04 0.4 C12-13 0.2 0.2 0.01 0.02 0.1 C14 |
| Lapyin 56 0 | Stomach Small intestine Coton Rectum Anus Liver Gallbladder etc. | 153 31 440 425 37 84 84 | 0 0 2 1 0 1 | 0.9 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 0.1 0.4 0.1 | 0.1 0.1 1.4 1.2 | 2.3 1.5 0.3 | 1.1 0.4 4.8 3.0 0.3 0.6 0.4 | 1.6 0.4 5.8 4.6 0.4 0.3 1.6 | 2.5 0.3 9.0 6.8 0.8 1.4 2.5 | 4.0 0.5 10.0 10.5 1.2 1.6 1.8 | 5.6 1.0 11.7 14.3 0.4 1.4 2.6 | 5.9 2.0 18.4 19.0 2.0 3.1 2.5 | 9.9 0.9 21.5 19.7 1.7 5.1 4.3 1.3 | 5.7 0.9 14.0 17.9 1.2 5.7 2.7 | 1.4 1.3 0.08 0.16 1.2 C16 0.3 0.3 0.02 0.03 0.3 C17 4.1 3.7 0.23 0.43 3.5 C18 4.0 3.5 0.21 0.41 3.3 C19-20 0.3 0.3 0.02 0.04 0.3 C21 0.8 0.7 0.03 0.07 0.7 C22 0.8 0.7 0.05 0.08 0.7 C23-24 0.7 0.6 0.05 0.07 0.6 C25 |
| Other chain 192 1 | Larynx Trachea, bronchus and lung Other thoracic organs | 56 330 26 | 0 | 0.2 | 0.1 | 0.9 | - | 0.1 | 0.1 | 0.8 | 0.1 2.1 0.1 | 0.4 2.0 0.6 | 0.9 4.3 0.3 | 0.8 5.7 0.6 | 1.2 7.4 0.2 | 1.4 10.6 0.8 | 1.7 16.7 0.8 | 3.0 17.2 0.9 | 2.7 9.2 0.3 | 0.5 0.5 0.03 0.05 0.4 <i>C32</i> 3.1 2.8 0.17 0.34 2.6 <i>C33-34</i> 0.2 0.2 0.02 0.02 0.2 <i>C37-38</i> |
| Broast 3234 9 | Other skin Mesothelioma Kaposi sarcoma | 192 10 0 | 0 0 | - | - | - | - 1 | - | - | - | 0.7 | 0.4 | 1.3 | 2.9 | 0.4 | 5.8 0.6 | 0.6 | 0.4 | 0.3 | 1.8 1.6 0.08 0.18 1.5 C44 0.1 0.1 0.01 0.01 0.1 C45 0.0 0.0 0.00 0.00 0.0 C46 |
| Vulya | | | | 0.3 | 0.6 | 0.4 | | | | | | | | | | | | | | |
| Renal pelvis | Vulva Vagina Carrix uteri Corpus uteri Uterus unspecified Ovary Other female genital organs | 22 45 895 513 155 783 23 | 0 0 2 0 3 1 | 0.3 | 0.1 | 0.1 | | 0.1 0.1 0.3 2.0 0.3 | 0.4 0.5 1.6 | 0.2 1.1 0.6 0.4 3.9 | 0.1 4.7 1.0 0.3 3.6 | 0.3 8.4 2.3 1.3 8.1 0.3 | 0.4 0.4 14.4 4.7 2.2 13.9 | 0.5 0.3 22.0 12.9 2.2 17.0 | 0.9 25.3 16.7 4.7 21.1 | 0.2 1.8 24.9 21.9 5.6 | 0.3 1.7 34.3 22.6 4.5 28.6 | 0.4 2.1 33.0 20.2 8.2 18.0 | 3.6 2.7 24.4 9.5 5.7 15.8 | 02 0.2 0.01 0.01 0.2 C51 0.4 0.4 0.02 0.04 0.3 C52 8.4 7.5 0.51 0.84 7.0 C53 4.8 4.3 0.30 0.52 4.0 C54 1.5 1.3 0.08 0.15 1.2 C55 7.4 6.3 0.46 0.70 6.3 C56 0.2 0.2 0.01 0.02 0.2 C57 |
| Strain, nervous system 171 0 0.6 1.3 1.1 1.2 0.3 1.2 1.5 1.8 1.8 3.6 2.2 2.1 3.2 2.0 3.0 1.5 1.6 1.4 0.11 0.13 1.5 C73 C73 C73 C74 | Renal pelvis Ureter Bladder | 1 4 98 | 0 | 0.9 - - - | 0.7 | 0.1 | - | 0.1 | - | 0.2 | 0.3 | - | | - | 0.2 | 0.2 0.2 3.4 | 0.6 | - | 6.0 | 0.0 0.0 0.00 0.00 0.0 C65 0.0 0.0 0.00 0.00 0.0 C66 0.9 0.8 0.04 0.10 0.8 C67 |
| Non-Hodgkin lymphoma 322 0 1.1 0.5 0.4 0.5 0.5 1.6 1.8 2.5 1.7 1.9 5.1 7.2 8.6 11.0 15.0 10.4 3.0 2.7 0.17 0.30 2.6 0.285 5.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0. | Brain, nervous system Thyroid Adrenal gland | 171 1175 15 | 0 1 0 | 0.6 | 1.3 0.1 0.1 | 0.7 | | | | 18.2 | | 19.7 | | 14.1 0.3 | 15.1 | 3.2 16.1 | 2.0 | | 1.5 | 1.6 1.4 0.11 0.13 1.5 C70-72 11.1 9.8 0.76 0.88 9.8 C73 0.1 0.1 0.01 0.01 0.1 C74 |
| Myeloid leukaemia 215 I 0.8 0.3 1.0 0.5 0.6 0.5 1.5 1.6 1.7 2.4 3.1 4.9 5.4 5.9 6.0 6.0 2.0 1.8 0.12 0.18 1.8 C92-94 Leakaemia unspecified 20 0 0.2 0.1 - 0.1 0.3 0.3 0.3 0.1 0.2 0.4 0.6 0.3 0.4 0.3 0.2 0.2 0.0 10.0 0.2 0.2 C95 Leakaemia unspecified 20 0 0.2 0.1 0.0 0.2 0.2 0.3 0.3 0.3 0.1 0.2 0.4 0.6 0.3 0.4 0.3 0.2 0.2 0.0 10.0 0.2 0.2 C95 Leakaemia unspecified 20 0 0.2 0.2 0.3 0.3 0.3 0.1 0.2 0.4 0.6 0.3 0.4 0.3 0.2 0.2 0.0 10.0 0.2 0.2 C95 Leakaemia unspecified 20 0 0.2 0.2 0.3 0.3 0.3 0.1 0.2 0.4 0.6 0.3 0.4 0.3 0.2 0.2 0.0 10.0 0.0 0.2 0.2 MPD Myelogyzplastic syndromes 19 0 0.1 0.5 0.2 0.4 0.8 2.6 0.9 0.2 0.2 0.0 0.0 0.0 0.0 0.0 MPD Myelogyzplastic syndromes 20 0 0.2 0.2 0.0 0.0 0.0 0.2 0.2 MPD Myelogyzplastic syndromes 20 0 0.2 0.2 0.0 0.0 0.0 0.2 0.2 MPD Myelogyzplastic syndromes 20 0 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0. | Non-Hodgkin lymphoma Immunoproliferative diseases | 322 | 0 | | | | 0.5 | | | | 2.5 | 1.7 | 1.9 | 5.1 | 7.2 0.2 | 8.6 | 11.0 | 15.0 | 10.4 0.3 | 3.0 2.7 0.17 0.30 2.6 C82-85,C96 0.0 0.0 0.00 0.00 0.0 C88 |
| All sites 12167 27 11.7 6.4 7.4 13.1 20.9 28.0 51.6 82.5 120.2 172.9 226.1 282.0 338.3 405.1 442.0 341.8 114.6 6.82 11.07 97.6 ALL | Lymphoid leukaemia Myeloid leukaemia Leukaemia unspecified Myeloproliferative disorders | 99 215 20 8 | 0 1 0 0 | 0.8 0.2 | 0.3 | | 0.5 | 0.6 | | | 1.6 | 1.7 0.3 | 0.3 2.4 0.1 0.1 | 0.6 3.1 0.2 0.2 | 0.4 4.9 0.4 | 1.0 5.4 0.6 0.2 | 2.5 5.9 0.3 | 1.3 6.0 0.4 0.9 | 1.5 6.0 0.3 0.6 | 0.9 0.8 0.05 0.07 1.0 C91 2.0 1.8 0.12 0.18 1.8 C92-94 0.2 0.2 0.01 0.02 0.2 C95 0.1 0.1 0.00 0.01 0.1 MPD |
| | | | - | | - | | | | | | | | | | | | | | | |
| AUSTIC DISTORTED TO THE TOTAL TO THE TOTAL TO THE TOTAL TO THE TOTAL TOT | | | | | | | | | | | | | | | | | | | | |
| Reference population: World Standard Population Table builtFri Dec 11 13:52:43 IST 2020 by CanReg5. | | | | 11.7 | 6.4 | 7.4 | 13.0 | 20.8 | | | | | | | 278.0 | 332.4 | 400.0 | 427.9 | 328.7 | 112.8 100.0 6.74 10.89 96.1 ALLbC44 |

33

Table 11 Childhood & Adolescent (0-19) Cancer Incidence Data according to International Childhood Cancer Classification (ICCC-3)

| Site | e Group | | ICD – O – 3 Histology | Male | Female | Total |
|---|--|------|---|------|--------|-------|
| Leukemias, myeloproliferative diseases, and myelodyspastic diseases | a. Lymphoid leukaemia | 9826 | Burkitt cell leukemia | 1 | 0 | 1 |
| | | 9835 | Precursor cell lymphoblastic leukemia, NOS | 61 | 33 | 94 |
| | | 9836 | Precursor B-cell lymphoblastic leukemia | 26 | 14 | 40 |
| | | 9837 | Precursor T-cell lymphoblastic leukemia | 9 | 3 | 12 |
| | b. Acute myeloid | 9840 | Acute myeloid leukemia, M6 type | 1 | 0 | 1 |
| | leukaemia | 9861 | Acute myeloid leukemia, NOS | 6 | 9 | 15 |
| | | 9867 | Acute myelomonocytic leukemia | 2 | 1 | 3 |
| | | 9872 | Acute myeloid leukemia, minimal differentiation | 1 | 0 | 1 |
| | | 9873 | Acute myeloid leukemia without maturation | 1 | 1 | 2 |
| | | 9874 | Acute myeloid leukemia with maturation | 6 | 5 | 11 |
| | | 9891 | Acute monocytic leukemia | 6 | 1 | 7 |
| | | 9910 | Acute megakaryoblastic leukemia | 1 | 2 | 3 |
| | c. Chronic myeloproliferative diseases d. Myelodysplastic | 9863 | Chronic myeloid leukemia, NOS | 6 | 2 | 8 |
| | syndrome and other myeloproliferative | 9946 | Juvenile myelomonocytic leukemia | 1 | 1 | 2 |
| | diseases | 9983 | Refractory anemia with excess blasts | 1 | 0 | 1 |
| | e. Unspecified and other specified leukaemia | 9800 | Leukemia, NOS | 1 | 2 | 3 |
| | | 9801 | Acute leukemia, NOS | 1 | 2 | 3 |
| | Total | | | 131 | 76 | 207 |
| Lymphomas and reticuloendothelial | a. Hodgkin lymphomas | 9650 | Hodgkin lymphoma, NOS | 7 | 2 | 9 |
| neoplasms | _ | 9651 | Hodgkin lymphoma, lymphocyte-rich | 0 | 1 | 1 |
| | | 9652 | Hodgkin lymphoma, mixed cellularity, NOS | 3 | 1 | 4 |
| | | 9653 | Hodgkin lymphoma, lymphocyte depletion, NOS | 0 | 1 | 1 |
| | | 9663 | Hodgkin lymphoma, nodular sclerosis, NOS | 3 | 0 | 3 |
| | | | | | | |

| Sin | te Group | | ICD – O – 3 Histology | Male | Female | Total |
|---|--|------|--|------|--------|-------|
| | b. Non-Hodgkin lymphomas(except Burkitt lymphoma) | 9591 | Malignant lymphoma, non-Hodgkin, NOS | 14 | 2 | 16 |
| | Y Y | 9680 | Malignant lymphoma, large B-cell, diffuse, NOS | 8 | 2 | 10 |
| | | 9690 | Follicular lymphoma, NOS | 1 | 0 | 1 |
| | | 9699 | Marginal zone B-cell lymphoma, NOS | 1 | 0 | 1 |
| | | 9702 | Mature T-cell lymphoma, NOS | 1 | 0 | 1 |
| | | 9714 | Anaplastic large cell lymphoma, T cell and | 0 | 3 | 3 |
| | | 9727 | Precursor cell lymphoblastic lymphoma, NOS | 10 | 2 | 12 |
| | | 9729 | Precursor T-cell lymphoblastic lymphoma | 3 | 1 | 4 |
| | c.Burkitt lymphoma d. Miscellaneous lymphoreticular neoplasms | | Burkitt lymphoma, NOS | 3 | | 3 |
| | | | Malignant histiocytosis | 0 | 1 | 1 |
| | | 9754 | Langerhans cell histiocytosis, disseminated | 6 | 10 | 16 |
| | e.Unspecified lymphomas | 9590 | Malignant lymphoma, NOS | 2 | | 2 |
| | T-4-1 | | | 2 | 26 | 2 |
| CNS and | Total | | | 62 | 26 | 88 |
| miscellaneous intracranial and intraspinal neoplasms | a. Ependymomas and choroid plexus tumour | 9390 | Choroid plexus carcinoma | 1 | 0 | 1 |
| | | 9391 | Ependymoma, NOS | 1 | 4 | 5 |
| | | 9392 | Ependymoma, anaplastic | 1 | 1 | 2 |
| | b. Astrocytoma | 9380 | Glioma, malignant | 1 | 1 | 2 |
| | • | 9400 | Astrocytoma, NOS | 3 | 3 | 6 |
| | | 9401 | Astrocytoma, anaplastic | 0 | 2 | 2 |
| | | 9420 | Fibrillary astrocytoma | 1 | 1 | 2 |
| | | 9440 | Glioblastoma, NOS | 3 | 6 | 9 |
| | c. Intracranial and intraspinal embryonal tumours | 9470 | Medulloblastoma, NOS | 5 | 3 | 8 |
| | | 9471 | Desmoplastic nodular medulloblastoma | 0 | 1 | 1 |
| | | 9473 | Primitive neuroectodermal tumor, NOS | 0 | 5 | 5 |
| | | | | | | |

| Site | e Group | | ICD – O – 3 Histology | Male | Female | Total |
|---|--|--------------|---|--------|---------|---------|
| | d. Other gliomas | 9380 | Glioma, malignant | 6 | 6 | 12 |
| | <u> </u> | 9450 | Oligodendroglioma, NOS | 0 | 1 | 1 |
| | e. Other specified intracranial and intrspinal neoplasms | 9362 | Pineoblastoma | | 1 | 1 |
| | f. Unspecified intrcranial and intraspinal neoplasms | 8000 | Neoplasm, malignant | | 2 | 2 |
| | Total | | | 22 | 37 | 59 |
| Neuroblastoma and other peripheral nervous cell tumours | a. Neuroblastoma and ganglioneuroblastom | 9490 | Ganglioneuroblastoma | 0 | 1 | 1 |
| tumours | | 9500 | Neuroblastoma, NOS | 15 | 5 | 20 |
| | Total | | | 15 | 6 | 21 |
| Retinoblastoma | V. Retinoblastoma | 9510 | Retinoblastoma, NOS | 9 | 17 | 26 |
| | Total | | | 9 | 17 | 26 |
| Renal tumours | a. Nephroblastoma and other nonepithelial renal tumours | 8960 8963 | Nephroblastoma, NOS Malignant rhabdoid tumor | 9 | 12 0 | 21 1 |
| | | 8964 | Clear cell sarcoma of kidney | 0 | 3 | 3 |
| | B. Renal carcinomas | 8260 8310 | Papillary adenocarcinoma, NOS Clear cell adenocarcinoma, NOS | 1 1 | 0 0 | 1 1 |
| | Total | 8312 | Renal cell carcinoma, NOS | 1 13 | 0 15 | 1 28 |
| Hepatic tumours | a. Hepatoblastoma | 8970 | Hepatoblastoma | 6 | 9 | 15 |
| | b. Hepatic carcinomas | 8140 | Adenocarcinoma, NOS | 1 | 0 | 1 |
| | Total | | | 7 | 9 | 16 |
| Malignant bone tumours | a. Osteosarcoma | 9180 | Osteosarcoma, NOS | 17 | 9 | 26 |
| | | 9181 | Chondroblastic osteosarcoma | 1 | 0 | 1 |
| | b. Chondrosarcoma | 9230 | Chondroblastoma, malignant | 0 | 1 | 1 |

| C. Ewing tumours and related surcomas of bone Parish to bone Parish | Sit | e Group | | ICD – O – 3 Histology | Male | Female | Total |
|--|-----------------------|--|------|-------------------------------------|------|--------|-------|
| Malignant bone tumours 9250 Giant cell tumor of bone, malignant 1 0 1 1 1 1 1 1 1 1 | | related sarcomas of | 9260 | Ewing sarcoma | 5 | 10 | 15 |
| Part | | malignant bone | 9250 | Giant cell tumor of bone, malignant | 1 | 0 | 1 |
| Malignant bone tumours 8000 Neoplasm, malignant 0 1 1 1 1 1 1 1 1 1 | | | 9370 | Chordoma, NOS | 1 | 0 | 1 |
| National Soft tissue and other extraosseous sarcoma Soft tissue and other extraosseous sarcoma Soft tissue and other extraosseous sarcoma Soft tissue Soft tissue sarcoma Soft tissue Soft tis | | malignant bone | 8000 | Neoplasm, malignant | 0 | 1 | 1 |
| Soft tissue and other | | | 8800 | Sarcoma, NOS | 0 | 1 | 1 |
| National Properties of the extraoseous sarcoma Secure 1 Secu | | Total | | | 25 | 22 | 47 |
| September Sept | other extraosseous | | 8900 | Rhabdomyosarcoma, NOS | 2 | 4 | 6 |
| B920 Alveolar rhabdomyosarcoma 0 | Surcomu | | 8910 | Embryonal rhabdomyosarcoma, NOS | 4 | 2 | 6 |
| b. Fibrosarcomas, peripheral nerve sheath tumours, and other fibrous neoplasms 9540 | | | 8912 | • | 1 | 0 | 1 |
| Peripheral nerve Sheath tumours, and other fibrous Post | | | 8920 | Alveolar rhabdomyosarcoma | 0 | 1 | 1 |
| 9340 tumor 1 | | peripheral nerve sheath tumours, and other fibrous | 8811 | · | 0 | 1 | 1 |
| 9361 rhabdomyoblastic differentiation 9580 Granular cell tumor, malignant 0 1 1 | | | 9540 | | 3 | 1 | 4 |
| d. Other specified soft tissue sarcomas 8806 Desmoplastic small round cell tumor 8963 Malignant rhabdoid tumor 9040 Synovial sarcoma, NOS 2 2 4 9041 Synovial sarcoma, spindle cell 9043 Synovial sarcoma, biphasic 1 0 1 9120 Hemangiosarcoma 1 0 1 9130 Hemangioendothelioma, malignant 9130 Malignant tenosynovial giant cell 1 0 1 9252 Malignant tenosynovial giant cell 1 0 1 9260 Ewing sarcoma 0 1 1 | | | 9561 | | 0 | 1 | 1 |
| Soft tissue sarcomas Soft tissue sarcoma Soft tissue | | | 9580 | Granular cell tumor, malignant | 0 | 1 | 1 |
| 9040 Synovial sarcoma, NOS 2 2 4 9041 Synovial sarcoma, spindle cell 1 0 1 9043 Synovial sarcoma, biphasic 1 0 1 9120 Hemangiosarcoma 1 0 1 9130 Hemangioendothelioma, malignant 0 1 1 9252 Malignant tenosynovial giant cell tumor 0 1 1 9260 Ewing sarcoma 0 1 1 | | | 8806 | Desmoplastic small round cell tumor | 3 | 1 | 4 |
| 9041 Synovial sarcoma, spindle cell 1 0 1 9043 Synovial sarcoma, biphasic 1 0 1 9120 Hemangiosarcoma 1 0 1 9130 Hemangioendothelioma, malignant 0 1 1 9252 Malignant tenosynovial giant cell tumor 0 1 1 9260 Ewing sarcoma 0 1 1 | | | 8963 | Malignant rhabdoid tumor | 0 | 1 | 1 |
| 9043 Synovial sarcoma, biphasic 1 0 1 9120 Hemangiosarcoma 1 0 1 9130 Hemangioendothelioma, malignant 0 1 1 9252 Malignant tenosynovial giant cell tumor 0 1 1 9260 Ewing sarcoma 0 1 1 | | | 9040 | • | 2 | 2 | 4 |
| 9120 Hemangiosarcoma 1 0 1 9130 Hemangioendothelioma, malignant 0 1 1 9252 Malignant tenosynovial giant cell tumor 0 1 1 9260 Ewing sarcoma 0 1 1 | | | | | 1 | 0 | 1 |
| 9130 Hemangioendothelioma, malignant 0 1 1 9252 Malignant tenosynovial giant cell tumor 0 1 1 9260 Ewing sarcoma 0 1 1 | | | | - | 1 | 0 | 1 |
| $ 9252 \begin{array}{c} \text{Malignant tenosynovial giant cell} \\ \text{tumor} \\ \\ 9260 \end{array} \begin{array}{c} \text{Ewing sarcoma} \\ \end{array} \begin{array}{c} 0 \\ 1 \\ 1 \\ \end{array} \begin{array}{c} 1 \\ 1 \\ \end{array} $ | | | | _ | _ | | 1 |
| 9252 tumor 0 1 1 1 9260 Ewing sarcoma 0 1 1 | | | 9130 | - | 0 | 1 | 1 |
| č | | | | tumor | 0 | 1 | 1 |
| 9364 Peripheral neuroectodermal tumor 1 0 1 | | | | _ | 0 | | 1 |
| | | | 9364 | Peripheral neuroectodermal tumor | 1 | 0 | 1 |

| Sit | e Group | | ICD – O – 3 Histology | Male | Female | Total |
|--|--|------|-------------------------------------|------|--------|-------|
| | e. Unspecified soft tissue sarcomas | 8800 | Sarcoma, NOS | 4 | 1 | 5 |
| | tissue sarcomas | 8801 | Spindle cell sarcoma | 1 | 1 | 2 |
| | Total | | • | 24 | 20 | 44 |
| Germ cell tumours, trophoblastic tumours, and neoplasms of gonads | a. Intracranial and intraspinal germ cell tumours | 9080 | Teratoma, malignant, NOS | 1 | | 1 |
| | b. Malignant extracranial and extragonadal germ cell tumours | 9080 | Teratoma, malignant, NOS | 1 | 3 | 4 |
| | | 9085 | Mixed germ cell tumor | 0 | 2 | 2 |
| | c. Malignant gonadal germ cell tumours | 9060 | Dysgerminoma | 0 | 4 | 4 |
| | | 9064 | Germinoma | 0 | 2 | 2 |
| | | 9071 | Yolk sac tumor | 2 | 3 | 5 |
| | | 9080 | Teratoma, malignant, NOS | 1 | 6 | 7 |
| | | 9085 | Mixed germ cell tumor | 1 | 2 | 3 |
| | d. Gonadal carcinoms | 8441 | Serous cystadenocarcinoma, NOS | | 1 | 1 |
| | | 8460 | Papillary serous cystadenocarcinoma | | 1 | 1 |
| | | 8461 | Serous surface papillary carcinoma | | 1 | 1 |
| | | 8470 | Mucinous cystadenocarcinoma, NOS | | 2 | 2 |
| | | 8480 | Mucinous adenocarcinoma | | 1 | 1 |
| | e. Other and unspecified malignant gonadal tumours | 8000 | Neoplasm, malignant | | 2 | 2 |
| | Total | | | 6 | 30 | 36 |
| Other malignant epithelial neoplasms and malignant melanomas | a. Adrenalcortical carcinomas | 8370 | Adrenal cortical carcinoma | 2 | 1 | 3 |
| | b. Thyroid carcinomas | 8260 | Papillary adenocarcinoma, NOS | 5 | 31 | 36 |
| | - W 111 0 111 W | 8290 | Oxyphilic adenocarcinoma | 0 | 1 | 1 |
| | | 8330 | Follicular adenocarcinoma, NOS | 0 | 6 | 6 |
| | | | | | | |

| | Site Group | | ICD – O – 3 Histology | Male | Female | Total |
|--|---|------|--|------|--------|-------|
| | | 8335 | Follicular carcinoma, minimally invasive | 0 | 1 | 1 |
| | | 8337 | Insular carcinoma | 0 | 1 | 1 |
| | | 8340 | Papillary carcinoma, follicular variant | 1 | 8 | 9 |
| | | 8341 | Papillary microcarcinoma | 0 | 2 | 2 |
| | c. Nasopharyngeal carcinomas | 8010 | Carcinoma, NOS | 1 | 1 | 2 |
| | | 8072 | Squamous cell carcinoma, large cell, nonkeratin | 2 | 0 | 2 |
| | d. Malignant melanomas | 8720 | Malignant melanoma, NOS (except juvenile melanoma) | 1 | 1 | 2 |
| | e. Skin carcinomas | 8071 | Squamous cell carcinoma, keratinizing, NOS | 1 | 0 | 1 |
| | | | Nodular hidradenoma, malignant | 0 | 1 | 1 |
| | f. Other and unspecified carcinomas | 8010 | Carcinoma, NOS | 2 | 0 | 2 |
| | | 8050 | Papillary carcinoma, NOS | 0 | 1 | 1 |
| | | 8070 | Squamous cell carcinoma, NOS | 2 | 1 | 3 |
| | | 8130 | Papillary transitional cell carcinoma | 3 | 0 | 3 |
| | | 8140 | Adenocarcinoma, NOS | 1 | 1 | 2 |
| | | 8430 | Mucoepidermoid carcinoma | 0 | 4 | 4 |
| | | 8452 | Solid pseudopapillary carcinoma | 0 | 1 | 1 |
| | | 8480 | Mucinous adenocarcinoma | 1 | 0 | 1 |
| | | 8500 | Infiltrating duct carcinoma, NOS | 0 | 1 | 1 |
| | Total | | | 22 | 63 | 85 |
| Other and unspecified malignant neoplasms | a. Other specified malignant tumours | 9050 | Mesothelioma, malignant | 1 | | 1 |
| | b. Other unspecified malignant tumours | 8000 | Neoplasm, malignant | 3 | 6 | 9 |
| | | 8004 | Malignant tumor, spindle cell type | 1 | 1 | 2 |
| | Total | | | 5 | 7 | 12 |

Mortality of Cancers

Mortality data due to cancers were obtained through the (i) Annual Health Bulletin based on Indoor morbidity mortality return (IMMR) from the hospital statistics and (ii) Department of Census & Statistics website based on data derived from the vital registration system of Sri Lanka.

Table 12: Deaths due to neoplasms at the government hospitals in Sri Lanka 2005-2013

| Year | No. of hospital deaths due to | Crude hospital annual death rate due to cancers per | Proportionate Mortality Ratio (PMR) out of all |
|------|-------------------------------|---|--|
| | cancers | 100,000population | hospital deaths |
| 2005 | 2753 | 14.0 | 8.3 |
| 2006 | 3241 | 16.3 | 9.9 |
| 2007 | 3498 | 17.5 | 10.1 |
| 2008 | 3485 | 17.2 | 9.8 |
| 2009 | 3774 | 18.5 | 10.0 |
| 2010 | 4449 | 21.5 | 11.1 |
| 2011 | 4631 | 22.2 | 11.8 |
| 2012 | 4519 | 22.2 | 11.6 |
| 2013 | 4539 | 22.2 | 11.2 |

Sources: Annual Health Bulletin 2005 to 2013.

Table 13 : Deaths due to neoplasms out of all registered deaths (hospital & field) 2001 – 2013 in Sri Lanka

| Year | Population | Cancer deaths | | | | |
|-------|------------|---------------|------|---------|--|--|
| | | No. | CR | PMR (%) | | |
| 2001 | 18,797,000 | 8,063 | 42.9 | 7.1 | | |
| 2002 | 18,921,000 | 7,986 | 42.2 | 7.1 | | |
| 2003 | 19,173,000 | 8,396 | 43.8 | 7.3 | | |
| 2004 | 19,435,000 | 9,127 | 47.0 | 7.9 | | |
| 2005 | 19,644,000 | 9,403 | 47.9 | 7.1 | | |
| 2006 | 19,958,000 | 10,386 | 52.3 | 8.8 | | |
| 2007 | 20,039,000 | 10,631 | 53.1 | 8.9 | | |
| 2008* | | | | | | |
| 2009 | 20,450,000 | 11,286 | 55.2 | 8.8 | | |
| 2010 | 20,653,000 | 11,836 | 57.3 | 9.1 | | |
| 2011 | 20,892,000 | 12,267 | 58.7 | 10.0 | | |
| 2012 | 20,359,439 | 12,581 | 61.8 | 10.2 | | |
| 2013 | 20,585,041 | 12,954 | 62.9 | 10.2 | | |

^{*} Not published

CR-Crude annual death rate due to cancers per 100,000 population

PMR - Proportionate Mortality Ratio out of total deaths

Table 14: Deaths due to cancers out of all registered deaths by sex in hospitals & field in Sri Lanka, 2005 – 2013

| Year | | Male | | | Female | |
|-------|------|------|------|------|--------|------|
| | No. | CR | ASR | No. | CR | ASR |
| 2001 | 4375 | 46.7 | 52.1 | 3688 | 39.1 | 39.9 |
| 2002 | 4350 | 46.5 | 51.2 | 3636 | 37.9 | 38.6 |
| 2003 | 4614 | 48.7 | 53.6 | 3782 | 38.9 | 39.6 |
| 2004 | 4942 | 57.1 | 57.3 | 4185 | 42.9 | 44.0 |
| 2005 | 4983 | 50.9 | 57.0 | 4420 | 44.8 | 45.8 |
| 2006 | 5644 | 57.1 | 63.6 | 4742 | 47.6 | 48.7 |
| 2007 | 5827 | 58.5 | 65.4 | 4804 | 47.6 | 48.8 |
| 2008* | | | | | | |
| 2009 | 6105 | 60.2 | 67.6 | 5181 | 50.3 | 52.0 |
| 2010 | 6438 | 62.8 | 70.9 | 5398 | 51.9 | 53.5 |
| 2011 | 6641 | 64.0 | 72.5 | 5626 | 53.5 | 55.3 |
| 2012 | 6908 | 70.1 | 65.5 | 5673 | 54.0 | 44.4 |
| 2013 | 7166 | 71.9 | 67.4 | 5788 | 54.5 | 44.9 |

Sources: Department of Census & Statistics

CR-Crude annual death rate due to cancers per 100,000 population

ASR – Age standardized annual death rate due to cancers per 100,000 population




Figure 8 - Age standardized mortality rates due to cancers in Sri Lanka 2001 -2013

^{*} Not published

Table 15 Leading sites (ICD-10) of cancer mortality – Male Sri Lanka 2013

| Type of Cancer | No | % | CR | ASR |
|--|------|----------|------|------|
| 1-034 Malignant neoplasm of trachea, bronchus and lung | 902 | 12.6 | 9.1 | 8.5 |
| 1-027 Malignant neoplasm of lip, or al cavity and pharynx | 863 | 12.0 | 8.7 | 8.1 |
| 1-031 Malignant neoplasm of liver and intrahepatic bile ducts | 491 | 6.9 | 4.9 | 4.7 |
| 1-028 Malignant neoplasm of oesophagus C15 | 371 | 5.2 | 3.7 | 3.4 |
| 1-045 Leukaemia C91-C95 | 314 | 4.4 | 3.2 | 3.1 |
| 1-029 Malignant neoplasm of stomach C16 | 272 | 3.8 | 2.7 | 2.5 |
| 1-042 Malignant neoplasm of meninges, brain and other parts of | 251 | 3.5 | 2.5 | 2.4 |
| central nervous system | | | | |
| 1-030 Malignant neoplasm of colon, rectum and anus C18-C21 | 205 | 2.9 | 2.1 | 1.9 |
| 1-040 Malignant neoplasm of Prostate C61 | 159 | 2.2 | 1.6 | 1.5 |
| 1-043 Non-Hodgkin s lymphoma C82-C85 | 154 | 2.1 | 1.5 | 1.4 |
| 1-026 Neoplasms C00-D48 | 7166 | 100.0 | 71.9 | 67.4 |

Table 16 Leading sites (ICD-10) of cancer mortality – Female Sri Lanka 2013

| Type of Cancer | No | % | CR | ASR |
|---|------|-------|------|------|
| 1-036 Malignant neoplasm of breast | 688 | 11.9 | 6.5 | 5.3 |
| 1-034 Malignant neoplasm of trachea, bronchus and lung | 331 | 5.7 | 3.1 | 2.6 |
| 1-038 Malignant neoplasm of other and unspecified parts of uterus | 294 | 5.1 | 2.8 | 2.2 |
| 1-027 Malignant neoplasm of lip, oral cavity and pharynx | 289 | 5.0 | 2.7 | 2.1 |
| 1-045 Leukaemia C91-C95 | 284 | 4.9 | 2.7 | 2.4 |
| 1-028 Malignant neoplasm of oesophagus C15 | 242 | 4.2 | 2.3 | 1.9 |
| 1-029 Malignant neoplasm of stomach C16 | 234 | 4.0 | 2.2 | 1.8 |
| 1-042 Malignant neoplasm of meninges, brain and other parts of | 220 | 3.8 | 2.1 | 1.8 |
| central nervous system | | | | |
| 1-039 Malignant neoplasm of ovary C56 | 213 | 3.7 | 2.0 | 1.7 |
| 1-031 Malignant neoplasm of liver and intrahepatic bile ducts | 207 | 3.6 | 1.9 | 1.6 |
| 1-030 Malignant neoplasm of colon, rectum and anus C18-C21 | 167 | 2.9 | 1.6 | 1.3 |
| 1-026 Neoplasms C00-D48 | 5788 | 100.0 | 54.5 | 44.9 |







National Cancer Control Programme Ministry of Health 555/5 Public Health Complex Elvitigala Mawatha, Narahenpita, Colombo 05 Sri Lanka